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ABSTRACT
Influenza is a highly infectious illness caused by the influenza A or B viruses.
Together with the high infectivity rates, relatively short incubation period and the
genetic lability of the influenza virus, influenza can cause overwhelming epidemics
and thus become extremely problematic to world public health (Bannister et al.,
1996: 131-134). Influenza and influenza-like syndromes are responsible for one third
of absenteeism in the workplace and it is due to this that prophylactic and curative
measures have become necessary (papp et al., 1998: 69-76).
In homoeopathy it is known that treatment of an epidemic with the genus epidemicus
remedy should be effective in the majority of cases (Kent, 1979: 33-39). This remedy
is carefully chosen on account of its similarity to the main presenting symptoms
displayed in all cases of the respective year's influenza picture. The aim of this study
. was to demonstrate the effectiveness of the genus epidemicus remedy indicated for
the current year's influenza epidemic, namely Arsenicum album. It was administered
in a 30CH potency.
The efficacy of the genus epidemicus remedy in the treatment of influenza was
assessed by investigating the intensity and duration of influenza symptoms over a
specified period of time, this being four days, in a suitable sample group. The sample
group was selected and obtained in a clinical setting. The sample group was randomly
divided into an experimental group and a control group of fifteen participants
respectively. Symptoms were monitored with the use of a questionnaire (Appendix
C). Placebos were administered to the control group and Arsenicum album 30CH was
administered to the experimental group. The medication was administered as a single
dose of five pillules three times daily. The first dose of medication was administered
in the clinician's office on commencement of the study and the following. six doses
were to be taken three times daily, in the morning, at lunch and in the evening, by the
participants themselves.
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Data was analysed by means of the Mann-Whitney statistical test. The experimental
and control groups were analysed separately. Group A was determined to be the
control group and Group B was determined to be the experimental group.
Effectiveness ofArsenicum album 30CH in the treatment of influenza was defined as
a statistically significant greater decrease in the symptom severity over time in the
experimental group, Group B, as compared with the control group, Group A.
From statistical evaluation it was determined that the homoeopathic remedy,
Arsenicum album 30CH, was the indicated genus epidemicus remedy for the
influenza epidemic of the winter of 2001. It was further determined that Arsenicum
album 30CH was effective in reducing the severity of symptoms of influenza or
influenza-like syndrome and was thus effective in the treatment of influenza and
influenza-like syndrome.
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CHAPTER ONE
INTRODUCTION
1.1. Problem statement
Influenza is a highly infectious illness affecting 10% to 20% of the adult population
and up to 40% of children. Influenza can cause overwhelming epidemics and thus
become extremely problematic to world public health (Bannister et al., 1996: 131-
134). Influenza and influenza-like syndromes are responsible for one third of
absenteeism in the workplace and it is due to this that prophylactic and curative
measures have become necessary.
A homoeopathic genus epidemicus remedy, namely Arsenicum album 30CH, was
selected and used as the treatment in this study.
1.2. Hypothesis
It is anticipated that the genus epidemicus remedy, Arsenicum album 30CH, will
decrease the severity and duration of influenza symptoms.
1.3. Purpose of the study
The purpose of this study was to determine the efficacy of the genus epidemicus
remedy, Arsenicum album 30CH, in the treatment of influenza and influenza-like
syndromes.
1.4. Importance of the problem
It is anticipated that the genus epidemicus remedy, Arsenicum album 30CH, will be
effective in decreasing the severity and duration of influenza symptoms. If it is
proven that the genus epidemicus remedy is effective, then this study will promote
the use of Arsenicum album 30CH in the treatment of influenza. This would help
decrease the need for anti-viral drugs and vaccination against influenza; This study
would then also initiate further research into the use of the genus epidemicus remedy
for the prevention and prophylaxis of influenza in the future.
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CHAPTER TWO
LITERATURE REVIEW
2.1. Influenza
2.1.1. Defmition
§ _Int!~~~Js a moderate to severe acute YirJlLrespiI!!!ory disease characte~sed~~~
fever, coryza, cough, headache, malaise and inflamed respiratory mucous
'__'''_M''A..,.
~~~~enza is~y infectious to those ~~~~:~~~:.~~_.~e_~~:as~~~._~a.:n
lead to significant morbidity and mortality. It usually occurs as an epidemic in the
" ._._, ~_-A~'_"_'_ _.-.....'""-,~_ ... .... ·•.• ~A__ ~,,,_. .._..._.._.~ ...'.... ~_..
winter (Schoub, 2000: 54-56).
-_...~...-.... ~..-. .
Influenza is spread by droplet inhalation of infected respiratory parti~les _f!~p:.1._,!!?­
i~~£~d to ~ susc.~tib~_person. The. infection usually begins i~ the .!!.acEe~.~~~~~~~1
l3?ith~JimlLwller..e Vin!Lr~pJi~~.!i9n_Q.~cU!,§.. T!!~.!.!.¥.'ec~ion_~t.~~~. spreads throughout the
• "-_~~,~"............ , .."-_... _,,,• ..., .• __•. _ •..,._,. •.~ .• , __,,',. • c
r,~~P!!l:l.lQry..tr~gl~ ..Th~.!~~!!Q.~tiQ!1,_pe.riog. QfJh~_y.!!11~£Q.1)!I!lE>.p.1Y_1:Wo._to. ..three .days.
The virus is detectable within 48 hours of contact and peaks around day three of the
...._"'..•.~._ ",~.,."""'" _'._" -.,.'r::•. _ " .~..".•.-.-- ..'~F ' '<~_, ,..""__",,.__._.. ,.. .. _ _.._ __ .....: ~__ ~'------- --.-n - "',.."",' ' " ""'.
i.!!f~_~!iQIt@4Jh~ILf.alls tol<!~ lev~s by'~ fiY:~JFleming, 2001: 189-193).
Influenza is a global disease with major public health importance. In a typical year,
influenza will cause illness in 10% to 20% of the adult population and in up to 40%
of children (Schabas, 2001: 36-37). Influenza is the cause of serious illness and even
many deaths. This is particularly so in the elderly and in patients suffering from
chronic illness such as asthma, chronic obstructive pulmonary disease,cardiovascular
disease and also in immunocompromised or immunosuppressed patients (Fleming,
2001: 189-193). There is increasing evidence concerning the importance of influenza
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as a cause of significant illness in young children and pregnant women (Schabas,
2001: 36-37).
~ 2.1.2. Clas.ifitafu>n.
The influenza virus was. one of th~ first h~~s~~to be !§91ated in 19?3-'py
~aidl.a~ AngreJY~~and.Smith..Ilis,.a~y.im.~_~hi<?!!.h~J'~~.!!.~.!!t~ns~!y_~~gl£9..f2!.!!1.!!!!Y
decades as itj~-L~latiy~Jx.s~X_,to_wo_'Y.i!!.l~ge am~ts_~~tuQY. ap~,i!liY,
bio~J!e~UY-..J.tnlc.llu:.ally_.aJ1~L!11.QJ~£!!!m:!Y. The influenza virus has also been
investigated extensively for many years in human volunteers and in field studies
(Schoub, 2000: 54-56),
The influenza viruses are cl~sifil;JLllS-9..rthqIlU2~,Q..Yi1"J!~~S_~JldJl[~diyjqe~Qjp~,Q_ty.m~~j\,
Jt£m~(B.j~hau;l~..9..s;J22.::l2.~J:b~J}v..Q.Jl!~i!l.!YR~!!!:Q,\ls..~_xirus~s.~that ...ar~
of i~ortance ~th tt?g~J!Q!ic he~lt.h.~.£l!ill,~nzaw~_an.<L!!Jf1!:!~~~... . The
i.!!flut?!1,?;~L&_Yl!1l.§)sJh~.J!}g~Lf!:~_ql!,~m".~ingle cause oL~linical influenza (Timbury,
1997: 37-43). Infeq~!Q.~'Li~.tr~mitted by person-to-person contact via airborne
-- .. .. _ ......._.~'c_·~"""-~......76~'··_.·,_.,~._ ...,',"........', ".',,_' ,_, ,.: ...... '. ...,.,.....
~.P!~l~QnU;'-!Collier and OXford, 1993: 132).
Influenza viruses are 80mn to 120mn in size with a core of helical ribonucleic acid
(RNA) and a soluble nucleoprotein (NP) antigen. The virion nucleocapsid is
enveloped in a membrane containing .two principal glycoproteins, one having
haemagglutinin (H) activity and the other having enzymatic activity as a
neuraminidase (N) (Beers et al., 1999: 192-196).
Influenza A and B are res£~nsibleJOI eE~e~ics of respira~rr.~U!p"~,~~Jha.t.o.~cur
~~~~~- .
.wmQLe..~ winter. and.J\L(LQfl~I1-~J)Q.Gj.ate.<lIDtPJnc~.!.2..!~!es.foE..hg.~jl~til)~t.i9.n,",
~.(l£!~Jlth..(Simonsen et al., 2000: 831-837). h1f1.uenza.type,C.<liffe.Es frQm types A
,"'~. ,.... ~._ ••. ,~'<I" ...o.·,-_(:.~.,,, >• .'. ~ '-~.,
l:lp.<iJl.jl1Jh'ltjt~£fH!~eS either a mild respiratory illness or no symptoms at all.
. -"'Uo>!t"~"""'''''''''~~;'';'''.......~.r''J'';~, .....,_ 'U).....=,~:.i);,...,. ~.':.:_ .", :.-c._."-•• "'<.'"·r-'-h~,,"~' ..' ......",...... "~.,~."'-:,,.F"••;.., "_,~:.-"",~~..".!,,",,,_";'AoJ''''''';''-'''"""''''''_"'''"'''''''_'':''';'~~''_';'.,__ ,•.. . ... , < .... _. ,. __ ~
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prl1ue~....ciE.cul~!e~~_I!l.9§t"wjllt~:r~.,.,,~iJh~,..,J\S_§nQl:adiG.,.JQ~~U~s£L.QY!!?!~a.!c!.,2~ ....~_
.wides'preadepid~~~. The physical structur~Q.f the vin,I,!m.~s it RaI1!f~l!!!!!Jx..£ro~
tp small surf~e ch~ges in an~!~~~.E~~~Most of the mutations are not
propagated because they are neutral Of lethal to the virus (Richards, 1998: 122-125).
Minor changes in the antigenicity of the virus surface glycoproteins, a process known
as antigenic drift, occur continuously and can result in epidemics. Antigenic drifts
render immunity to the influenza virus short-lived. Because of this, large portions of
the population are susceptible to influenza every year. Antigenic drift is also one of
the main factors in the origination of an epidemic of influenza (Schoub, 2000: 54-56).
The influenza A virus can undergo additional major changes in the surface
glycoproteins, or even genetic re-assortments. These changes contribute to antigenic
shift. In this case, a new subtype of the virus suddenly emerges (Fleming, 200 I: 189-
193). Antigeni.C? sNf1§~jl£~_!e~p.2!!§.ili!~ for ,1.!llP.g~!E. .. ~Wlll~~~_~.p:'.lI~L~_~~~.: of
mortality (Richards, 1998: 122-125).
~"''''··'''-.'''''ot''__ ·;'''·''_'
Influenza type A viruses are further divided into subtypes based on differences in
their viral proteins called the haemagglutinin (H) and the neuraminidase (N).
Different serotypes of influenza A are numbered A(HIN1), A(H2N2) and A(H3N2),
according to the major surface antigens of influenza strains that have caused
epidemics in humans since the virus was first isolated in 1933. Since 1977, both
A(H3N2) and A(HIN1) types have been responsible for prevalent disease.
Differences in the specific influenza B surface antigens (H and N) are not assigned
numbers. Influenza C is not a prevalent virus, and if serotypes occur, they are not
defined. A(HIN1) strains are more likely to infect younger persons, aged 35 years or
younger, while A(H3N2) strains infect all age groups (Beers et al., 1999: 192-196).
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2.1.3. Life-cycle of influenza virus
Myxoviruses attach via the haemagglutinin to a specific receptor on the cell surface.
The virus is engulfed, its envelope fuses with the vacuolar membrane and the viral
genetic material enters the cell. After intracellular replication of the viral components, .
the virus is assembled at the cell surface and is then released from the cell by a
budding process involving the viral neuraminidase (Bannister et al., 1996: 131-134).
The primary site of virus multiplication is the superficial epithelium of the lower
respiratory tract where it causes damage to the cilia and desquamation of the
epithelium (Timbury, 1997: 37-43).
2.1.4. Epidemiology
( Epidemics of influenza occur during the winter months every year. Attack rates
\
\ during epidemics seldom exceed 10% in the general community but may be much
\
'I higher in closed institutions and among school-age children. Complication rates and
\ mortality rates are, however, greatest in the elderly and those with underlying chronicIconditions (Bannisteretal., 1996: 131-134).
J
Influenza is a disease that manifests in seasonal epidemics. These epidemics occur as
a result of minor changes in the influenza viral antigenic proteins. Occurrence of
epidemics has been associated with influenza A viruses. Influenza B viruses also
cause epidemics and are largely restricted to human beings, whereas all human
influenza A viruses infect avian species. The significance of this is that sometimes
influenza A viruses jump species from birds to infect humans. Avian species and
other animals are thought to be reservoirs of influenza and may play a particularly
important role in creating a favourable environment for antigenic shifts (Cox, 2000:
30). Currently there are three different influenza strains circulating world-wide: two
subtypes of influenza A and one of influenza B (WHO, 2001).
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. ,
(:
tigeniC drift is responsible for the yearly epidemics as new subtypes of
•. haemagglutinin slowly evolve. Infection with an epidemic strain provides antibodies
which will cross-react with closely related haemagglutinin types and confers partial
If immunity to infection by slowly evolving types from year to year. Antigenic drift
\
•. occurs in the virus because of selection pressure imposed by the partial immunity of
\
. thepopulation (Bannister et 01., 1996: 131-134). Evolution of a new strain of virus as
a result of antigenic shift results in widespread influenza activity because the
\ population has little or no cross-reacting antibody to the 'new' virus and a pandemic
\\\ results (Schoub, 2000: 54-56).
\
'1
'I
i Factors that will determine the severity of an influenza epidemic include:
• Antigenic drift: the characteristic property of the influenza virus to continually
change its antigenicity ensures that there will be a continual supply ofnew viruses
to produce regular epidemics (Hampson, 2000: 55). This continual antigenic
change in the outermost haemagglutinin attachment protein of the virus allows it
to partially escape the protective immune response of the human host. The impact
of these viruses poses a particular threat to certain 'risk groups' in which it may
exacerbate underlying conditions and predispose secondary bacterial infection
(Schoub, 2000: 54-56). The following are considered to be part of the risk group:
individuals over 65 years of age
adults with chronic debilitating illness
children with cyanotic congenital heart disease
adults and children on immunosuppressive therapy
residents ofnursing homes and chronic care facilities
• Influenza in the Northern hemisphere the winter of 2000: influenza activity in the
Northern hemisphere during the winter months provides an indication of what
will happen in the following winter in the Southern hemisphere approximately six
months later (Schoub, 2000: 54-56).
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• Ambient weather conditions: there is no proven association between the severity
of weather and the extent of influenza, but observations indicate that weather
conditions may playa determinant role (Schoub, 2000: 54-56).
To estimate the extent of the epidemic and the impact it has on the population, certain
parameters are measured (Schoub, 2000: 54-56). These parameters include:
absenteeism in schools and industry, percentage of general practitioner visits due to
influenza-like illnesses, mortality rates in the elderly and consumption of
pharmaceuticals related to respiratory tract infections such as antibiotics, cough
mixtures and decongestants.
These indicators have been widely used in studies to determine cost-effectiveness of
influenza vaccines. These parameters need to be examined in direct relation to virus
isolation in order to get an appreciation of the epidemiological impact of influenza
and to avoid other causes ofabsenteeism (Schoub, 2000: 54-56).
Despite the enormous wealth of information available on influenza, a virus which has
been studied for so many decades, scientific tools are still not available to be able to
predict the severity of forthcoming influenza epidemics (Schoub, 2000: 54-56).
2.1.5. Historical background
Influenza-like disease was well described by Hippocrates in 412 B.C. The first
convincingly recorded epidemic in Europe was in 1173-1174, and the first pandemic
recorded was in 1580. Since this period, thirty-one possible influenza pandemics have
been documented. Modem influenza epidemiology began with the 1889 pandemic.
The periodicity of pandemics from 1580-1889 was around 18-34 years and from
1889-1977 ranged from 9-39 years. This periodic renewal of the vitality of the
8
influenza virus, seemingly more frequent over the last one hundred years, can lead to
gross loss oflife (Shortridge, 2000: 29).
Pandemic influenza is the most serious predictable health emergency. A new
pandemic strain has the capacity to spread world-wide in a matter of months. There
have been three influenza pandemics in the twentieth century (Schabas, 2001: 36-37):
1918-1919: Spanish flu A(HIN1)
1957-1958: Asian flu A(H2N2)
1968-1969: Hong-Kong flu A(H3N2)
Each of the three pandemics this century (1918, 1957, 1968) were associated with
,
high rates of morbidity, social disruption and high. economic costs. The 1918
pandemic claimed more than twenty million victims world-wide in less than one year
(Cox, 2000: 30). The overall clinical attack rate was as high as 40% with severe
forms of pneumonia being a common occurrence. The attack rate and mortality rate
were generally highest in twenty to fifty year old adults (WHO, 2001). The pandemic
was caused by a type A(HIN1) influenza virus related to a virus found in pigs
(Shortridge, 2000: 29).
The history ofprevious pandemics and pandemic trends shows that new sub-types of
influenza A virus do not appear at defined intervals and all occurrences of human
infection with a novel sub-type of influenza A virus cannot be expected to lead to a
pandemic (WHO, 2001). It is now clear that there is no predictable time frame or
'cycle' after which a pandemic will occur. Another natural pandemic of influenza is
likely to strike. It cannot be predicted when it will happen or how serious it will be.
This concern is based on observations from past centuries and on current knowledge
about the avian and swine reservoirs for influenza viruses and' the mechanisms for
emergence of novel pandemic strains. Increases in global travel and world population
during the past century will probably contribute to more rapid spread of pandemic
influenza in the future (Cox, 2000: 30).
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The unpredictability of influenza and the serious consequences that can occur when a
pandemic does appear, provide ample justification for constant vigilance and good
planning, to improve preparedness, if another pandemic virus does appear. The time
from the first recognition of a new subtype and the onset of a full-blown pandemic
may be too short to prepare a vaccine and utilise it (WHO, 2001).
2.1.6. Clinical features
During the 48 hour incubation period, the patient may be asymptomatic before the
onset of symptoms of infection occur (Richards, 1998: 122-125). Influenza A and' B
are rapid in onset, with chilliness and fever, up to 39,5°C, developing over twenty-
four hours. Prostration and generalised aches and pains, particularly of the legs and
back, appear early. Headache is a prominent feature" often with photophobia and
retrobulbar aching (Collier and Oxford, 1993: 131). Symptoms relating to the
respiratory tract may be mild at first, with a scratchy sore throat, substernal burning,
non-productive cough and occasionally coryza. The cough can become severe and
productive as the illness progresses (Richards, 1998: 112-125).
Other respiratory. features include tracheitis, croupy cough, laryngitis and possibly
sinusitis (Bannister et al., 1996: 131-134). The skin, especially on the face, is warm
and flushed. The throat may be reddened, but there is no exudate. The conjunctiva
may be inflamed and the eyes water easily. Also present are nausea, anorexia and
fatigue. The acute symptoms usually last for no more than five to seven days, but the
fatigue, weakness and cough may persist for some.weeks. The fever may last up to
five days without complications (Richards, 1998: 112-125).
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2.1.7. Diagnosis of influenza
The diagnosis of influenza is made on the presenting clinical picture. Investigations
ofuncomplicated influenza are unnecessary and unhelpful (Richards, 1998: 122-125).
Rapid confirmation of the diagnosis of influenza is possible with several new in-
office assays that can detect the presence of influenza A and B within ten to twenty
minutes. The sensitivity of the tests range from about 60% to 85%. The specificity is
greater than 90% (McCarthy, 2000: 22).
The assays allow clinicians to reach a specific, confirmed diagnosis fairly
inexpensively as well as quickly. Before these tests were available, specimens had to
be collected and sent to a laboratory, where the assay process involved the growing of
influenza virus from the specimen. To arrive at a specific diagnosis could take so long
that the disease might have run its course before it was identified as influenza. With
the new diagnostic tests, the clinician can determine within a very short time what
illness the patient has and concentrate then on choosing the best treatment. There are
currently three in-office assays available:
FLU OlA®: is an optical immunoassay. This test is designed to detect
influenza nucleoprotein in nasopharyngeal swabs, sputum and nasal aspirates.
The test takes approximately fifteen to twenty minutes to complete. FLU
OlA® has a sensitivity of77% and a specificity of93%.
Quickvue'"; detects viral nucleoprotein by means of monoclonal antibodies.
Nasal swabs or aspirates are mixed in a solution so as to disrupt the particles
of the virus. Detection reagent on a test strip is immersed in the solution for
ten minutes. The strip changes colour in the presence of influenza antigens.
Quickvue'" sensitivity ranges between 73% and 81%, its specificity is
between 95% and 99%.
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Zstat Flu®: detects influenza neuraminidase activity by means of an enzyme-
based assay. The test requires that a throat swab be incubated with a synthetic
neuraminidase substrate at 41°C for twenty minutes. In the presence of
neuraminidase, the substrate produces a blue colour. Zstat Flu® has a
sensitivity of 65% for influenza A and 57% for influenza B; its specificity for
the two strains ranges between 95% and 100% (McCarthy, 2000: 31-32).
These assays are most useful early and late in the influenza season, since at the height
of an epidemic it is relatively easy to make a clinical diagnosis of influenza. In a
recent study the presenting symptoms of fever and cough were found to be reliable
predictors of influenza if they occurred when influenza was known to be circulating
in a community (Fleming, 2001: 189-193). A major benefit of the new diagnostic
tests is that they can reduce the inappropriate use of antibiotics and facilitate the
appropriate use ofantiviral agents (McCarthy, 2000: 31-32).
2.1.8. Complications
In the large majority of cases influenza is an acute, self-limiting upper respiratory
tract infection, however, complications can occur. Complications involving the lower
respiratory tract occur from secondary bacterial, mixed viral-bacterial or viral
infections. Complications may also occur through exacerbation of pre-existing
chronic disease, particularly cardio-pulmonary disease. Cardiac complications have
also been observed in previously healthy young adults (WHO, 2001).
Young infants and pregnant women appear to be at risk of increased hospitalisations
from influenza, as do other persons of any age whose ability to cope with a chronic
condition is compromised by influenza infection. Usually the most serious
consequences are seen to increase with age, particularly above the age of 65 years
(WHO, 2001).
12
Secondary bacterial infection is a common complication and is suggested by
deteriorating lung function (Bannister et al., 1996: 131-134). Encephalitis,
myocarditis and myoglobinuria may occur as complications of influenza, usually
during convalescence, in people with debilitated immune systems or in the
chronically ill. Croup, exacerbation of chronic obstructive pulmonary disease and
pneumonia are all recognised with influenza infections. The most life-threatening of
these is pneumonia. Apart from secondary bacterial infection there are few
complications (Collier and Oxford, 1993: 131).
a. Pulmonary complications
• Pneumonia
Three types of complicating pneumonia have been described:
1. Bacterial infection is the most common. It may occur in previously healthy
persons after the influenza virus has damaged the epithelium in the airways. It
also may occur in those persons with underlying disease rendering them more
susceptible to bacterial infections (WHO, 2001). Secondary bacterial infection
should be strongly considered in patients who report a severe fever or the
reappearance of fever or other symptoms of bacterial infection in the
respiratory tract after the initial influenza illness has improved
(Bannister, et al., 1996:131-134).
11. Combined viral and bacterial pneumonia is less common.
in. Pure viral pneumonia is rare but the influenza virus can be a cause of acute
pneumonia infection (Carr-Bains, 1999: 54-56).
The main presenting symptoms of pneumonia include cough, coloured sputum,
wheezing, fever, malaise and chest pain. The pain may arise from the muscular effort
of coughing or be pleuritic due to underlying lung parenchymal damage. There may
also be dyspnoea and cyanosis. Confusion can occur, especially in the elderly, as a
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consequence of hypoxia. Clinical signs and symptoms can be very atypical in the
elderly. An increased respiratory rate of over thirty breaths per minute suggests :
serious infection. If not resolved, death may result from asphyxia, sepsis and toxic
shock syndrome, or cardiac arrythmias. Staphylococcal pneumonia is common in the
community in association with an influenza epidemic (Carr-Bains, 1999: 54-56).
Viruses are the most common cause of pneumonia in children with the influenza
virus being of major importance (Canny, 1999: 62-66). Rapid progression over the
first few days, after onset of high fever and cough, to severe dyspnoea and cyanosis,
are consistent with a diagnosis of severe influenza virus pneumonia (WHO, 2001).
Additional important risk factors for both primary and secondary bacterial infections
of the respiratory tract are cigarette smoking (including passive smoking), abnormal
secretions, anatomical or functional abnormalities and deficiencies of both humoral
and cellular immunity (Brink, 1998: 715).
b. Non-pulmonary complications
• Cardiac complications
The most common cardiac complication is atrial fibrillation, particularly in older
persons. ECG changes during acute influenza are noted in patients who have cardiac
disease, but these have been ascribed to exacerbation of the underlying cardiac
disease rather than to direct involvement of the myocardium with influenza virus.
Left or right cardiac failure may occur. Myocarditis and pericarditis are believed to
occur in rare cases and may be fatal (WHO, 2001).
• Myositis and Rhabdomyolisis
Involvement of muscles as a complication of influenza has been reported most
commonly after influenza B infection in children. Symptoms include leg pains and
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muscle tenderness that lasts for one to five days. Acute myoglobinuria may result in
acute renal failure due to tubular necrosis (WHO, 2001).
• Central nervous system complications
Transverse myelitis and encephalitis occur rarely. Mania and schizophrenia were
associated with the 1918 pandemic (WHO, 2001).
• Reye's syndrome
This is a rare hepatic and central nervous system complication seen after viral
infections, in particular influenza B infection. Reye's syndrome occurs almost
exclusively in children and is linked with the use of salicylates. Presenting symptoms
include a change in mental status and nausea and vomiting due to oedema of the brain
(WHO,2001).
2.1.9. Allopathic treatment
The basic treaID1enLfoLin.fluen~ is SYIDlltommic. Antipyretics are-llQtJ!.§.l!~.Hy
necessary. AS]2irin. is co.!!tr~ind!£~~~~__i~,~~~~,~~~!1_E,~f~!!~_~~gJjt~ ..~~.~s()~!~tion with
g~)'~'~s_~YnQrQ~ (Bannister et al., 1996: 131-134). 11J.~[~j!?!!9_~!~*~_JQLilllJi9.io!ic;;
!Ulle~$Jb~I~J!'(~A~~ndaJ:Y.£J)JDllli~atiolls({;OX, 2000: 30). The,patient .shQuld_n~J:!l~~I!.
~e(!. or r~~lad.~flqately'~c! avoi.4.£~.~rti9!Ldur..ing the acute stage of the disease and
-- ""~..~,.-..o;~"'--__._C;._·>,_-__,.·__ ",·,·,-",,,·~·,,·,",·,,.'·'·.
[~1Lhpur~L.afteLthe. temperature..hasnormalised, (Beers et al., 1999: 192-196).
TI!!.~_,~~~~~s~_~atJh~".wyocardium'.'i~"protected_-.fi:Q,m,_~e~~~§.~_~~~,,~n~._ ()x,ygen
desaturation is 1imited.(Bannister et al., 1996: 131-134).
If constitutjon&Jl1!!!P~J!l.f~;.;~l',~~ut~.ptlC.!J~E~.i~~~~dinfluenza are severe, anti-
i¢J.'!e~_91leII}otherapy,_l!ntipY[~!ic:s~~,,~alg~~~~~~~~JlelpftI1. Thes.e.,~]1ould be
gi~eIl: p!~PJ2r.opriAte,J:lo~es,"and intervals.. ,,Flqig.§. ~lIQ.llJp.,QeJ~e!J.q!i'~ely !l~.Pfolonged
~~".,Je."\lef and anorexia will predispose to. > dehydration. Vaporisers and
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humidification may help relieve the c2n~es!!£~~~ol.!g~~~A.~itt?~~t.Ig~~!~!,!?
relieve nasal Qh~tI1lctioRm<!Y be considered for temporary use (Richards, 1998: 122- .
.-......_..,,,'-~_.._.-e-_.•_ ... --I~,.-_ .,-"- _. . - '~~~"""""''':''''~;<;;;>':;:;''''_''''.""."".,.;."_,,:;,,,,.,•._,...'~ '',_..,;~._, .,.'~~: __ ..'.: .,
125).
Although allopathic treatment advocates the influenza vaccine ~e Qrim'!!Ywa~
preventing influenza, antiviral drugs are considered an important adjunct to the
---.;;:"--_.~------~---,."._~-,_._-_..- ._-_._---_.__..-._"~--_._ .._-.."-.
vaccine for the control and prevention of influenza. Currently there are four approved
~-'---~~-"-''''''''''''-~:_'''''~''''_'''''Il',_.-",,, ·~'''''_''',,,,,,,,,
antiviral medications available: amantadine, rimantadin~';~~i;i;~d~~seltanuvir-
.~__,,,,,;""'~_~'~_·__ """_'.-:'G·""~_'_::,,,~,,,_··,:...,,~...,~ ..",.""~""'_'''''.'>''''''''.'''_,"~.",.",."",~",,,,,,.,~.~,,_, .....,,,.'~·'_:H__""~" ......,....-..",.... ,,",,,,,,_. ............,,,...o.;,,,,, .. ~~-.....~•.....,~. .,._"_,,,,,,-,,,_.,,,,,",,,_
(CDC, 2001).
a. Amantadine and Rimantadine
The antiviral agents amantadine an~ riman~ili!!~ which have similar antiviral
"-..._-, ,
~otency ~~ainst_infll!~A, were developed more than thirty years ago. Both drugs
are approved for the chemoprophylaxis and treatment of influenza A infection only.
When administered prophylacticaJly to healthy adults or children, both amantadine
>. ., . -
and ri.~~~d~ne..~~~py:roxi~x...?2~~ !2,.??:y.0.effe.~2.~~Yre~~j~!:~~,~J:~!E..._
. _ .. 1-"""
. influenza A,infect!£.u. When administered as a treatment within two days of illness
onset in healthy adults, amantadine and rimantadine can reduce the severity and
duration of signs and symptoms of influenza A illness by approximately one day. To
reduce the emergence of antiviral drug-resistant viruses, amantadine and rimantadine
treatment should be discontinued as soon as clinically warranted, generally after three
to five days of treatment or within 24-48 hours after the disappearance of signs and
symptoms (CDC, 2001).
1Pantad~~d_riIl1anta4iI)~h<!v~ ,,<l!l()Ifl~.. ~ioav~J'!l>ility. ()fgr~.~!.~~~~,~.20% and
half-lives of 10-31 hours and 25-36 hours respectively. The efficacy of amantadine in
~.....,··~...c .....--~·~...-.,:.._...., .. i'."~,,~,, __ ,,, -"'-~··"'·"'"-'--'-"-"""""''''''':·"'"'~~'''''''''''''~J'C-.",.."..-.• . '_ "",,',", .•.,"....__.<~.'" ...._..,.:_._.•..: ~_-...-~_._._._. ._~_'.'._ '". ,_,~_" • __
~young adults has been demonstrated, but a majouliSllilY~~e is its narro\\,__
therapeutic range. This has caused particular problems in the elderly, where peak
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serum levels may be as much as three times higher than in those under 65 years of
age. Amantadine is eliminated in the kidneys by glomerular filtration and tubular .
secretion. This method of eliminating is thought to be responsible for the doubling of
half-life seen in the elderly, possibly because renal function decreases with age.
Patients with renal insufficiency also require careful monitoring if treated with
amantadine (Fleming, 2001: 189-193).
Rimantadine has similar efficacy to amantadine and is generally better tolerated
because it is predominantly eliminated via the liver (Fleming, 2001: 189-193).
Amantadin(}andrimantl;l.dinejnbib!!...Yim1 rep.li~alliw~ In vitro, both drugs are potent
_~ ' _.~.~...,_..__ .-
inhibitors of most strains of influenza A virus. However, much higher concentrations
which cannot be achieved in vivo, are required to inhibit other respiratory viruses,
including influenza B. The clinical effectiveness of amantadine and rimantadine for
both prophylaxis and therapy of influenza A has been demonstrated in adults and
children. Both agents are effective in preventing influenza in individuals during
outbreaks of influenza A in the community, as well as in residents of institutions,
particularly the elderly and for post-exposure prophylaxis in children and adults in
households where influenza is circulating. Studies have shown a range of protection
from 40% to 80% in outbreaks of influenza A (Fleming, 2001: 189-193). When given
therapeutically, amantadine is about 80% effective in shortening the period of illness
(Hampson, 2000: 60).
One of the major drawbacks of both amantadine and rimantadine is the rapid
development of drug-resistant strains. The observance of cross-resistance between
amantadine and rimantadine has greatly limited the use of rimantadine despite it
being better tolerated (Fleming, 2001: 189-193). Adverse effects of amantadine
commonly include central nervous system effects such as nervousness, light-
headedness, lack of concentration, insomnia, delirium, hallucinations, seizures and
behavioural changes (Hampson, 2000: 60). These are thought to be due to the
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dopaminergic effects of amantadine and may be more common in patients who are
receiving concomitant antihistamine or anticholinergic therapy. Adverse effects of .
rimantadine include nausea, anorexia and headache (Fleming, 2001: 189-193).
Amantadine and rimantadine have never been widely used because of the rapid
development of drug-resistant strains, lack of effect against influenza B,
gastrointestinal side-effects and in the case of amantadine, central nervous system
side-effects (Fleming, 2001: 189-193).
b. Neuraminidase inhibitors
Influenza viruses are known to have two surface antigens- the haemagglutinin and the
neuraminidase. The minor antigen, the neuraminidase, is an enzyme that facilitates
the aggregation and release of the newly formed virus from infected cells and is thus
essential for the replication ofboth influenza A and B (Hampson, 2000: 60-61).
Two new antiviral agents active against both influenza A and influenza B, called
___'~_~. __'.". 'L-'-_",
zanaI12ix,!I.~P~ ~s~ltami-virr:are. the first members of a new class of antivirals c~g~_~_
m<uraminidase inhibitors. They reduce replication of influenza A and B by interfering
- .. -- ._.~===--:---:::-=-,_.-.- .. ."~.~,.~" ...--.-
~th neuraminidase. Zanamivir and oseltamivir received Food and Drug
Administration approval in 1999 for the treatment of uncomplicated influenza
infections (McCarthy, 2000: 34). Zanamivir is approved for individuals over twelve
years of age. Oseltamivir is approved for those over eighteen years of age (Winquist
et al., 1999: 1-9).
Clinical studies comparing treatment of influenza with neuraminidase inhibitors and
placebo indicated that these antivirals clearly do work, provided they are
administered within two days of the illness onset in otherwise healthy adults. Early
therapy can reduce the severity of symptoms as well as the duration of illness in some
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patients by as much as two days. The neuraminidase inhibitors have also been shown
to have prophylactic benefit in influenza. (McCarthy, 2000: 34:-39).
Clinical studies with zanamivir have shown that it is effective in the treatment of both
influenza A and B infections. When used therapeutically within thirty hours of onset
of symptoms, at two doses per day, zanamivir reduces the time of alleviation ofmajor
symptoms and resumption of normal activities by 1.5 to 2 days. This is similar to the
effectiveness ofamantadine (Fleming, 2001: 189-193).
Za.n!.!mivir-is adminisl~Led_by_oraUnhalation directly to the major site of viral:: .=x::- , ... .. .- -_....._-_.-.._ ..._-
~p-lication, the resl?i~at~ry t~ This method may, in part, contribute to its
gnpressive safety profile. In clinical trials with zanamivir to date there has been no
evidence of the development of drug-resistant strains. ~~amivir is the first antiviral
--.-.~---_.~_....._. " '"-._.- '.
agent that is well-tolerated and effective for the treatment of both influenza A and B.
'-:-:.--_¥ '*__._..- -.-_. .. .,."__~" .• ""'.; _._.>.,,,.~_ .•."' ~,".,_ _.-"_- _4.~4'_~,..~ ,.._._ '.• ._ "" _ ..__ ~., ..
Thus it~p.!~s~~!,~:-.~major ~gvancementov~J4e_QJb~LMtly!!~1~.~g~n~(Fleming, 200 I:
189-193). The drug should be useful in controlling outbreaks in nursing homes,
protecting the immunocompromised who do not respond to vaccination, and treating
high-risk individuals who may contract influenza despite vaccination or who have
failed to be vaccinated (Hampson, 2000: 61).
As zanamivir is ineffective against all other viruses, it should only be used for the
treatment of infections where there is a high probability that the causative agent is
influenza. Zanamivir should be used prophylactically only in the face of a true
outbreak (Hampson, 2000: 61).
The most common side-effects of zanamivir include diarrhoea, sinusitis, nasal
symptoms, bronchitis, cough, headache, dizziness and infections of the ear, nose and
throat (Winquist et al., 1999: 1-9). Zanamivir has been reported to be irritating to
patients with pulmonary disease, especially those with asthma or chronic obstructive
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pulmonary disease. Thus, zanamivir should be discontinued in any patient who
develops bronchospasm or a decline in respiratory function (McCarthy, 2000: 37).
Q§.eltamivir is approved for the chemoprophylaxis of influenza and is 60%-90%
effective in preventing illness from influenza infection. OseltamiYir is taken orall~
Side-effects of oseltamivir include nausea.xomiting and headache. These side-effects
may be dimLnishedif..the..dmg is taken with food (CDC, 2001).
There are three major disadvantages to the neuraminidase inhibitor drugs, Firstly, the
(~ . ..
narrowness of the clinical window of opportunity offered by !he neuraminidase
~bitors_limit~L.!h~-!!nJ~U:)f..pr.escrip..tL()11jp--!w0 days in order fqr the drug to be
~.. . "_."-
effective. Second!yz Eatient adherence is a troublesome issue as the therapeutic
regimen fQr bQthJ)~ur~iDjdas.es...specifiesJ.woJloses_p-eulay fQr fiye day-so If one
---.-.._._....-'~..,,~-~ ..~
dose is missed, patients~ find. th~iL~ym.pt()DJ~-r.eturning;.,ThlrdJy-~_~.<?~.t i~_~~_I?~jor
concern. A course of treatment with one of the newer antivirals has been estimated to:.:.=:..:=:.:...:..:...::..::.::.~.;:;..;;...;;:..;;.:.,;.;.::;;;;;,:;.~~;;;.;;.~;;;;...,;;..:;;~~. ---~------.-..'-- "----.~-
~15 t!~.~.~,,~~.~,",pensiveasam.~Ul~jn~!h~~~I'x..~~a~2~L7.:2.Jill!~sas ~~q?eIlsjy~~~
!imantadi!1e~eat~(McCarthy, 2000: 38-39).
The added benefits of a neuraminidase inhibitor include a wide therapeutic range,
fewer side-effects and a much reduced likelihood of the emergence of drug-resistant
strains. Thus, it is believed that the additional benefits of a neuraminidase inhibitor
are sufficient to justify the extra cost (Fleming, 2001: 189-193).
The March 2000 recommendations of the Advisory Committee on Immunisation
Practices (McCarthy, 2000: 37-38) note that no antiviral drug has demonstrated any
ability tQ prevent serious influenza-related complications such as bacterial or viral
pneumonia or exacerbations of chronic lung disease. The effectiveness that these
drugs have demonstrated has been in otherwise healthy patients with uncomplicated
influenza. Data remains limited or inconclusive concerning the usefulness of the
antivirals in patients at high risk of serious complications. Efficacy studies in children
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are scant. Some studies have found a prophylactic benefit with the new antivirals
resulting in a reduced use of antibiotics with fewer opportunities for bacterial
infection.
2.1.10. Vaccination
The first influenza vaccines were developed in the 1940s following the discovery that
influenza viruses could be cultivated in embryonated chicken eggs. The early
""':";--JI
vaccine.~£..ryde cqnc~trates of egg-grown viruses that had been chemically
iI!.~!!Y.a.!~,~r..~.jnijiillJ.Y used in the armed forces where they were found to be
h~ghlyJ?rotectiY~.lmt somew4at rea~~~. A sudden change in the antigens of the
circulating viruses in 1946 to 1947 demonstrated the need to update the vaccine
regularly to keep pace with changes in the circulating viruses. The development of
improved purification processes led to progressively purer vaccines. However, it was
not until the introduction of 'splitting', a process involving the disruption of the
vaccine virus with detergent or solvent, that the problem of systemic toxicity of
influenza vaccines in adult recipients was finally overcome (Hampson, 2000: 55-56).
Influenza vaccines differ from most conventional vaccmes, such as diphtheria,
,,__. .·••_ ..~.~v~_·.'~., __••_,_.,_~ __~ ••~ •.. _ .... _~ ... ~._ .._.
tetanus and polio vaccines, that typically confer lifelong immunity. Ongoing changes
in th~~eJl!lire vaccines to be reformulated every year. On occasion,
----- .. - --~-~--
~~re js.a ..Jess::tha.IeperfeCLmalcJLlwmeelLthe-.circ.ulating virus and the vaQ.gne
(Hampson, 2000: 55). Tb~._.IQle.._QUnfluenza....Y!lccination ~th.er.efore...not..for
.epidemiologi~a1_controLQLJ-9I. communi!Y-PJot~~on. Influenza va~cines_s~~t
Rrevent influenza epidemics in the same way as measles or polio vaccines have
-_ ...._----~.....--.._~.__.,..._~.._- •.- .~
~~§!!~PI!.~:...Th~.J~!~U!f th~i!lf.l.!1e~ va..£gi!1~~j~J.h~~~_~ersonaLp!~t~.ctJ01?-
",p.~.r.e,J.he_Yll~cine_iLhighly_effective...in..pr.ey~mi!!gJ!tE.::;:SQ.(e.::~~~~(,~..:....'W.<;l,.:Q~n
c..£.rnp!icat~d~r~Spi@lQJYJ.rclct \!Jf~£t!2.I}!.~!1~J~ ..~':l~~ Fhic.~.~.e.~~~~.~~pecially. in
the eld~rlY~cljl1.gthe!.~t:ri~tp~tiel1ts. Also, in otherwise healthy adults,.they ar~.
---~-;.,-,,",""''''-_'-...,,.,..-'- -<.,. .-. . - - ..- .. ..~-. ""-'-_"'~,.."",-:_._..- .~-.-.' . "'-'.~~
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highly effective in reducing absenteeism due to the debilitating effects of influenz~
(Schoub, 2000: 54-56).
Yaccines play an eS~Dtial role in the...m;:Ylj!~!!l~J1tjLfjnfluenza inJID~!!.-risk .woups,
-minimis.ing-ihe.....risk~QLJ~ontr<!91i!J,g. iqfluenza and of secondary complications.
~_~~~_""'-~"..:"~""'-'V·'~'"'·".'"'_'·':"""'", ,"",~."._; •._ , .•_,._/ _"'..~.
Nevertheless, there remains a major need for antiviral agents to treat breakthrough
infections for outbreak control in nursing homes and communal establishments and
for prophylaxis in situations where the circulating strain differs from the vaccine
strain (Fleming, 2001: 189-193).
Current vaccines are targeted mainly at older adults amLth.e_~hr.9.ni~ally. ill. Because
o_--~---_- __0_________ __ . - _
of this, vaccination has little influence on the spread of the virus through. the
----...,----,.._~..'_..' '"-- ." ..' p" ...... -"-.--_...-,,--~ ..,,--,.~.,,,..-
~cQPll1lumtyJ1til1?lmPjlct onJhe..lY..<?rkf'2!£~ This has stimulated the ongoing search for
____ ._,.-.....~...~·w .. _..,..",'" .....,,-"h+~,....~
new and better ways ofpreventing and treating influenza that has recently produced a
'" ---,-,,---_.""""-""""'- .
living attenuated vaccine and a new class of antiviral compounds (Hampson, 2000:
55-60).
Studies conducted over the last two decades that have. examined actual vaccme
_ . ~---"--'~'-'--- ..~.. . ."-". - _.. ~"---._'~"~'--'-""" ... _.'" - ·' =_:":'_7._::;;-_; ..;~_.~..,,-,=.~~,,--,-.:o.:....:-=
~ffectiveness have consist~nth~..sho.w.JL~ql.1!)Ym1i'!Lp.JQ~tive effect in older ~~':lJts,
including institution~..li~ed elderlY,.-iUld ag~!~!-J!!~-.s.evere out~es ~<?L.~I}!1!1~.nza
infectiol1... S.Qme-studies"h~y'~,_!!.t~Qj.fleI]1i.!1~.f!~_p!.~t~~,!~y~~~~g~i!!st ,_~Qnge.~t.ive
~~5!!~~.._f~lllf~;' ..PA~.9f th~.JI\~ill~~~~~~._of ..th~._e~~es~__mo~~~~!.~o~~:.~.~'!E,n~.
~J!~nza_Ql1tbreak$,_Th~re.J~.jD.xt:e.~!D-g.~.Yl(l~!!CJLfu~t iI!_QIQ~.L.?g!1J!§.jp.flll,~~a
v:~~e..,not_Qnly_a..highlY_~c'QsL~ffectiYe_jnte.r..vention, but may also be cost-
- ---... --..--.,,..._,,.......-:;.~-......_~.~_....,, __L,"" ..• _,..
~~ying. Similar economic benefits may extend to the immunisation. of healthy
working adults. Thus, the vaccines currently available are far more effective than
_______• ·-·.....-~_.. ..,"--·~~ ...... _ ........ ·.'....... ;>c .~_._·_._'•• _.,.~._ ..• _...
previously thougQ((Hampson, 2000: 56-58).
~.~"".,.,.,~.>O' •.. '"...,:..._"'~~~. '?:.f!C.,..,
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The protective effects conferred by influenza vaccination depend on the concordance
---
between vaccination and circulating strains. Overall vaccine effectiveness varies from
__-".'+-o.------------.---.-~.,.---,-
y~y~ar, depending on the degree of simil~.!Xbe~~~!!!!!-~i~l:l:enzavirus strains
included in the vaccine and the strain or strains that circulate during the influenza
----_._----~-----_.._.._._-_._---_ _ ' ..- --_ _-_ ~_... .", .. ,.
season. In the elderly and at-risk population, vaccination has been estimated to confer
-----
a 60% reduction in laboratory confirmed illness. Estimates of the clinical
effectiveness of vaccinating community-living elderly persons range from 20-60% for
hospitalisations for pneumonia; 20-40% for hospital admissions for respiratory
conditions; 0-40% for hospitalisations for congestive cardiac failure and 30-75% for
other causes ofmortality (Fleming, 2001: 189-193).
In healthy adults the vaccine efficacy is between 70% and 90%. Serious side-effects
--_..=:-_------------._--------_ _..., .
are very rare. There is compelling evidence that immunisation of groups at high risk
--------------,---~, ,.,.," ...•. "'"'«- ....... '.• ~.-. ",""', ,.<.,. "...••._.,~ .."~.~-~" ...~......", ••,-~,.,...,.~._~,_.'"~.-., •..,,'._.
for complications is co~~ffecti'ye. ~There is also evidence that immunisatiOJ;L.2[
children and healthy adults is also cost-effective (Schabas, 2001: 36-37).
The current strategy of immunisation of the high-risk population is ineffective at
protecting those at risk of complications. Two reasons for this are that coverage rates
are poor and the approach, whereby only the high-risk population is immunised, does
nothing to limit the spread of influenza in the community (Schabas, 2001: 36-37).
b. Limitations of the vaccine
Despite their benefits, currently available vaccin~s ha.Y~_JimitatiQn~...Eir.stly~().!lJ:e of
the older adult .eo..Qulation re~J>ond poorly to· the vaccines. Secondly, the vaccines are
.~..•~•.. , ........" .. "'.... _.,_.-... ,.- •..-~~ ..,.- ........ ,- "
not jdealJor routine vaccination of young~hil.4r~!1,th.elI1aintransmitters of infection.
Ithas beenspeculatedthat priming the immune system with infectious virus may
1)IQyig._e_,.;-an---imp()~!__~un2!9gic~I .... fOunda,tJQ:tl _.JQLresponses__~Q§ubsequent
influenza infections. Inactivated vaccines may not provide effective priming. Thirdly,
<., .• ""~-_.~,'_._ .•_,..-~.- .• __.._ .._~--.-~-.-..~,.,.,-"~~'~.-"_ .• ~,+~ .. ,"
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vaccine strains must be updated each year to maintain a h!gh level_ ofJ-,!.?tec..!i~E_~~."
the antibody res.poo£e.Jnduced bj' the vaccines_ is relatively short-lived (Hampson,
2000: 56-58).
c. Side-effects of the vaccine
While the influenza vaccine, like any other vaccine or medicine, is capable of causing
serious problems such as severe allergic reactions, the risk of the vaccine causing
serious harm, or death, is extremely small. The most common side-effect from the
influenza vaccination is soreness at the site of injection. The soreness can last up to
two days but is usually mild and does not affect a person's ability to perform their
normal daily activities. Some people, usually children, who have not been exposed to
the influenza virus in the past, may have fever and body aches after vaccination.
These symptoms, if they occur, usually start six to twelve hours after vaccination and
can continue for one to two days (CDC, 2001).
Less common side effects that can occur after vaccination include allergic reactions
and Guillain-Barre syndrome. Guillain-Barre syndrome is a severe paralytic illness
and is only a complication of the vaccine in a minority of influenza seasons,
occurring at a rate of about one in a million doses (Schabas, 2001: 36-37). Life-
threatening allergic reactions are very rare, but such reaction can occur in people who
have a severe allergic response to any vaccine component, most commonly allergy to
eggs (CDC, 2001).
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d. Target groups for vaccination
According to the Advisory Committee on Immunisation Practices (McCarthy, 2000:
28), vaccination is recommended for the following persons, who are at increased risk
for complications from influenza:
• Persons aged 50 years and older
• Residents of nursing homes and other chronic care facilities that house persons of
any age who have chronic medical conditions
• Adults and children who have chronic disorders of the pulmonary or
cardiovascular systems, including asthma
• Adults and children who required regular medical follow-up or hospitalisation
during the preceding year because of chronic metabolic diseases (including
diabetes mellitus), renal dysfunction, haemoglobinopathies, or
immunosuppression (including immunosuppression caused by medications or
HIV infection)
• Children and teenagers aged six months to eighteen years who are receiving long-
term aspirin therapy and therefore might be at risk of developing Reye's
syndrome after influenza infection
• Women who will be in the second or third trimester of pregnancy during the
influenza season.
Persons who are clinically or subclinically infected can transmit the influenza virus to
persons at high risk for complications from influenza. Decreasing transmission of
influenza from caregivers to persons at high-risk might reduce influenza-related
deaths. According to the guidelines of the Advisory Committee on Immunisation
Practices (McCarthy, 2000: 32), evidence from more than one study suggests that
vaccination of health care workers and others in close contact with persons at high
risk is therefore recommended, included are those listed here:
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• Physicians, nurses and other personnel in both hospital and outpatient-care
settings, including emergencyresponse workers
• Employees of nursing homes and.chronic care facilities and other residences for
persons in high-risk groups
• People who provide home care to persons in high-risk groups
• Household members (including children) of persons in high-risk groups.
Because the currently available vaccine is an inactivated vaccine, many experts
consider influenza vaccination safe during any stage of pregnancy. The influenza
vaccine does not affect the safety of mothers who are breast-feeding or their infants.
Breast-feeding does not affect immune response and is not a contraindication for
vaccination (CDC, 2001).
e. Live-attenuated vaccine
One major advance in influenza immunisation has been the development of a live-
attenuated ('cold-adapted') vaccine that is administered intranasally. Trials to date
suggest that the cold-adapted vaccine is unlikely to replace the current vaccines for
use in the older adult populations. However, it appears to be well suited for
immunisation of children. It does not produce the systemic reactions sometimes
induced by conventional vaccines but it provides similar immunological priming to
natural infection. This provides the exciting prospect of interrupting the spread of
influenza in the community and also preventing illness occurring in schoolchildren.
The vaccine may also find acceptance in members of the younger adult population,
particularly those averse to receiving injections (McCarthy, 2000: 27-28).
Obvious advantages of the new vaccine include ease of administration, the
substitution of a nasal spray for an injection and the introduction of a broad mucosal
and systemic immune response. In head-to-head clinical trials with inactivated
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vaccine, the live-attenuated vaccine was found to be equally effective. In clinical
trials with the live-attenuated vaccine overall efficiency among vaccinated children
was about 92% for influenza A and 87% for influenza B. It has been noted that the
live-attenuated intranasal vaccines probably will not replace injectable vaccines in
high-risk patients who are immunocompromised (McCarthy, 2000: 27-28).
2.2. Genus Epidemicus
2.2.1. Definition of Genus Epidemicus
The genus epidemicus refers to a prescription that is based upon Hahnemann' s
observation that during an epidemic of an acute disease the majority of cases will
respond to the same remedy. This holds true provided the remedy is chosen according
to the Law of Similars, that is, that the remedy exhibits similar symptoms to the
characteristic symptoms ofthe epidemic (Eizayaga, 1991: 234-235).
2.2.2. Prescribing technique
According to Hahnemann, the prescription ofa genus epidemicus remedy can only be
given once comprehensive knowledge of the complete picture of the disease, via
close observation ofseveral cases ofevery such disease, is obtained.
Hahnemann stated that it is possible to arrive at a characteristic portrait of the disease
by careful observation of even the first and second patients and therefore be able to
find a suitable homoeopathic remedy for the disease (Hahnemann, 1997: 183-185).
The most suitable homoeopathic remedy for the array of symptoms exhibited by the
epidemic at the time and is found to act curatively in the majority of cases, is termed
the genus epidemicus remedy. This genus epidemicus remedy is thought to be
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effective in the cure of the epidemic disease, as those people who are infected have
contracted the disease from the same source and hence are suffering from the same
disease (Kent, 1979: 33-39). Such a remedy will also act prophylactically for contacts
who have not yet developed symptoms ofthe disease (Watson, 1999: 23).
2.2.3. History of Genus Epidemicus
Ever since Hahnemann' s days, this so called genus epidemicus has been used in
epidemic infectious-contagious diseases. There have been a number of documented
cases where the genus epidemicus remedy had been used successfully in epidemics
(Blackie, 1986: 168-169). In 1801, Hahnemann used Belladonna as a treatment in an
epidemic of scarlet fever. Hahnemann found that the remedy Belladonna acted not
only curatively, but also prophylactically against the deadly epidemic. The results of
this triumph were published in 1801 in a pamphlet called 'The Cure and Prevention
ofScarlet Fever', now found in Hahnemann's Lesser Writings (Little, 2001: 83).
Probably the most significant historical example of the use of the genus epidemicus
remedy was in 1831 when the Asiatic cholera had reached epidemic proportions
throughout the whole of Western Europe. This disease was characterised by violent
diarrhoea, vomiting, abdominal colic and a high death rate. At the time, there was no
sure or effective conventional treatment for the disease. Some physicians even
resorted to venesection, the practice of draining large quantities of blood from the
patient, as it was thought that the reason for the fatal course of cholera was the
thickening of the blood on account of the enormous discharge of fluids. Many
patients died from the treatment rather than from the disease. Hahnemann, by the
application of his 'Law ofSimilars', was able to describe a curative and preventative
procedure based on reports of symptoms of Asiatic cholera provided by his nephew,
who was practising in St. Petersburg. The homoeopathic treatment of cholera proved
successful. Of the 1655 cholera patients in Raab, for example, only six of the 154
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patients treated homoeopathically died, whilst of the remainder, 821 treated
conventionally, died. Reports from other parts of Europe showed that the death rate
amongst patients treated with conventional means exceeded 50%. The death rate
amongst the patients treated homoeopathically.ranged from 21% to a lowest level in
Vienna of only 2.4%. This figure reported from Vienna was of particular significance
because, at this time, the practice of homoeopathy was illegal in Austria. The genus
epidemicus for the cholera was a cognate of three different remedies: Camphor was
to be given in the early stages, followed by Cuprum metallicum and Veratrum album
in the later stages of the disease (Cook, 1981: 155-159).
2.3. Homoeopathic Principles
2.3.1. Introduction
Homoeopathy has been branded as a 'non-science' for most of its two hundred year
history, certainly for as long as medical science has been founded on the principles
that are regarded as orthodox today. There is no explanation of the effects attributed
to homoeopathic medicines, but in recent years a series of papers have seriously
challenged the assumption that homoeopathic medicines are nothing but placebos.
These papers culminated in the challenging conclusion that either these infinitely
dilute preparations do have active properties, in spite of our inability to conceive what
they may be, or the double-blind placebo controlled trial is not a suitable or reliable
test ofefficacy (Swayne, 1998: 82-86).
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2.3.2. Law of Similars: 'Similia similibus curentur'
Eizayaga (1991: 234-235) defines Homoeopathy as 'a science and an art of curing
based on a natural biological law, called the "Law of Similars", according to which a
dynamic disease in an organism is cured in a durable manner with another stronger
disease ofdifferent species but similar in symptoms.'
The concept of treating with 'similars' is very ancient and was resurrected in the early
nineteenth century by Edward Jenner's use of the cowpox vaccination as a
preventative for smallpox. The 'similar' cowpox was seen to confer immunity against
smallpox (Coulter, 1980: 18-22).
It is known that Paracelsus and Hippocrates were aware of the principles of similia
and contraria, so it is assumed that Hahnemann, being a widely read scientist, got to
know ofthese principles from old medical literature (Debats, 1997: 34-37).
The Law of Similars is the defining principle of homoeopathy. Medicine must be
prescribed according to the Law of Similars which means that the appropriate remedy
for each sick person is the substance which would give rise to precisely the same set
of symptoms if administered to a healthy person (Coulter, 1980: 18-20).
Homoeopathic medicine is based upon the empirical principle that substances capable
of causing disorder or adverse effects when administered to healthy people can be
used as medicines to remedy similar patterns of disorder experienced by people when
they are ill. Homoeopathic medicines act therapeutically in patients whose clinical
picture is closely similar to the pathogenetic effects of the source material of the
medicine (Swayne, 1998: 143-144).
For effective treatment, the 'drug picture' must match the details of the illness or
'clinical picture'. The prescription must be the medicine whose drug picture most
closely resembles the clinical picture in the patient. This prescription is then termed
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the 'similimum', provided the chosen remedy does, in fact, affect cure. The most
specifically individual symptoms are of most value in selecting the similimum
(Swayne, 1998: 82-86).
The broader clinical picture, which encompasses any coexistent or past syndromes, as
well as the precise individual details of th~ complaint together provide the indications
upon which, ideally, a single prescription will be based. The better this totality is
reflected in the 'therapeutic repertoire of the chosen medicine, the better the response
in the patient. For the totality of symptoms to be cured, a medicine must be sought
whichis proved to have the greatest tendency to produce similar symptoms (Osawa,
2001:' 13-26). A good response will involve changes in several facets of the patient's
clinical state, not just the presenting picture (Swayne, 1998: 82-86).
2.3.3. Homoeopathy versus Allopathy
Homoeopathy differs from allopathic medicine, in that it possesses a precise set of
principles which govern diagnosis and treatment. Even with the entry of new
medicinal substances into homoeopathic practice, the principles themselves have not
changed (Coulter, 1980: 18-19). Homoeopathic principles and postulates are a
coherent body of knowledge describing the behaviour of an organism in sickness and
health and prescribing the method which must be followed to bring it from sickness
to health (Coulter, 1980: 97).
Allopathic therapeutic methods are disintegrative. They require that the patient is
treated as a collection of separate physiological and biochemical systems. A practical
problem arising from this is the possible burden of multiple prescriptions, especially
when there are side-effects or interactions or of multiple specialist referrals.
Similarly, different clinical episodes may be treated as unrelated events rather than
facets ofa coherent and evolving process (Swayne, 1998: 82-86).
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Homoeopathy insists on taking an integrated view of the clinical phenomena and the
personal characteristics and circumstances of the patient. The cost-effectiveness and
cost-benefits of this approach have yet to be properly investigated. The possibilities
of real clinical improvement as opposed to damage limitation with expensive long-
term maintenance treatment are attractive (Swayne, 1998: 82-86).
The principle of similars is, however, applied in allopathic medicine. The whole
development of immunology and serum therapy is founded on this principle. There
are also a number of drugs in common allopathic use whose efficacy is due to the fact
that they are employed according to' the principle of similars (Coulter, 1980: 69).
Thus, conventional medicine relies unconsciously on the homoeopathic Law of
Similars for many of its effective drugs. However, this law is applied in a crude way
in that it is applied without the individualising which is a necessity in homoeopathy
(Coulter, 1980: 70).
The principle difference is that homoeopathy is a precisely structured doctrine with
consistent and coherent ideas. Allopathy, in contrast, lacks a precisely defined and
delineated set of ideas. It accepts concepts, principles and procedures from any
number of sources, with the result that various parts of allopathic doctrine are at times
inconsistent (Coulter, 1980: 93-95).
The greatest contrast between the conventional and homoeopathic use of symptoms is
that in homoeopathy the most valuable symptoms are those that are not typical of
underlying pathology. In conventional medicine the reverse is true. In homoeopathy
the important symptoms are those that are the most characteristic of the patient and of
the behaviour of the illness in that specific patient. It is these symptoms that will most
clearly define the similarity between the clinical picture in the patient and the
characteristics of the medicine. The effective medicine will be the one in-which the
similarity is most complete (Swayne, 1998: 83-84).
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Homoeopathy and conventional treatment are not mutually exclusive. When a patient
is receiving conventional treatment then homoeopathy aims to achieve improvement
in the condition over and above what has been achieved with conventional
medication and ultimately to make the patient less dependant on or independent of
conventional drugs (Swayne, 1998: 143). Homoeopathy may, however, be more
difficult to apply in patients with a, history of prolonged substantial use of
conventional medicine (Swayne, 1998: 82-86).
Homoeopathy was unfortunate to emerge in the nineteenth century when the
pervasive engineering and scientific advances enshrined reductionist thinking in the
investigation of nature. As a unique form ofholistic medicine, homoeopathy naturally
met with incomprehension from physicians trained in the belief that reductionism was
the only true method in science (Coulter, 1980: 102-103).
2.3.4. Homoeopathy and vaccination
Vaccination is considered by many as being an example of allopathic use of the Law
of Similars. Whilst vaccines are small amounts of material which are capable of
producing disease in healthy people, they are administered to the entire population
without any consideration of individuality. Each individual will have a unique degree
of susceptibility to any vaccine. The vaccine is administered without taking into
consideration the uniqueness of each individual. Thus, the concept of vaccination
does not conform with the Law of Similars and is almost the precise opposite of the
principles of homoeopathy. Vaccination is the indiscriminate administration of a
foreign substance to everyone, regardless of state of health or individual sensitivity.
In homoeopathic terms, vaccination is considered to have a disturbing effect on the
health of an individual, particularly in relation to chronic disease (Vithoulkas, 1980:
113-117).
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Depending on the state of health of the individual, there are two basic types of
responses which can occur after vaccination. Firstly, there can be no reaction or,
secondly, there may be some degree of reaction. The lack of reaction can either
indicate a very healthy system or a system with a deep constitutional weakness. The
reaction is considered to be a sign of the defence mechanism responding to the
morbific stimuli of the vaccine. The degree ofreaction can be further subdivided into:
a mild reaction, a strong reaction with fever and other systemic symptoms, a very
strong reaction with complications such as encephalitis, meningitis, or paralysis
(Vithoulkas, 1980: 113·117).
A mild reaction indicates that the patient is susceptible to the disease against which
the person has been vaccinated. The defence mechanism is therefore not strong
enough to fully deflect the effect of the vaccine. Its morbific influence then remains
in the body. A strong reaction where systemic symptoms such as fever, malaise,
anorexia and muscle aches are produced indicates that the body is able to successfully
counteract the morbific influence of the vaccine. This type of reaction is commonly
seen in children. A very strong reaction with complications shows that the defence
mechanism is too weak to counteract the morbific stimulus of the vaccine, so deep
illness is produced. In homoeopathy, any chronic condition which can be traced to a
vaccination is called vaccinosis (Vithoulkas, 1980: 113·117).
A striking example of vaccinosis was in 1918 where entire populations were
vaccinated against the expected swine influenza epidemic. Out of over fifty million
Americans who were vaccinated, 581 developed Guillain-Barre syndrome. This
incidence presented a seven-fold increase over that of the population at large. From a
homoeopathic point of view such consequences are predictable whenever a foreign
substance is injected into large numbers of people without regard for individual
susceptibility (Vithoulkas, 1980: 113-117).
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With the use of homoeopathic medicines some of the possible problems related to
immunisation can be prevented. Homoeopathy can offer effective treatment for
naturally occurring diseases. The infectious diseases play an important part in the
development of a child and the naturally produced immunity is far more valuable than
that produced by immunisation (Blackie, 1976: 184-187).
2.4. Arsenicum album: the genus epidemicus remedy
The homoeopathic remedy, Arsenicum album 30CH, was chosen as the genus
epidemicus on account of the similarity between characteristic symptoms exhibited
by influenza patients of the current epidemic of influenza and the symptoms that
would require Arsenicum album as a homoeopathic treatment. It was found to be the
most suitable homoeopathic remedy for the influenza epidemic ofwinter 2001.
Influenza is generally rapid in onset and first signs of illness usually include
chilliness and fever up to 39.5°C (Collier and Oxford, 1993: 131). The patient
requiring Arsenicum album will be extremely chilly (Boyd, 1989: 178-179),
aggravated by the cold and desires heat. These patients may be chilly with sensations
of internal burning heat or the chilliness may alternate with heat. During such an
acute illness, patients requiring Arsenicum album wilt tend to have a hot head and
face and desire open air despite the coldness of the body and a desire for warm
covering. The Arsenicum album influenza patient will have a fever particularly from
12a.m-3a.m. This fever will often be worse or more pronounced around midnight to
la.m-2a.m in the morning (Morrison, 1993: 39-44). The patient will have symptoms
that are generally aggravated at night (Gagrat, 2001: 37-38) The Arsenicum album
patient will perspire at the end of the fever. The perspiration is cold and has a sour
smell or is offensive (Boger, 1995: 19-21).
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A prominent clinical feature of influenza is headache (Collier and Oxford, 1993:
131). In Arsenicum album influenza patients, these similar head complaints are
ameliorated by cold (Morrison, 1993: 39-44). The Arsenicum album patient suffering
from a headache will complain of a burning sensation in the head and will be very
sensitive to the smell of food, tobacco, or cooking (Blackie, 1986: 168-169). The
influenza headache is often accompanied by photophobia and retro-bulbar aching
(Collier and Oxford, 1993: 131). The Arsenicum album influenza is characterised by
intense photophobia as a result of concomitant iritis or conjunctivitis with ciliary
injection. There may also be ciliary neuralgia (Boericke, 1997: 79-83). The pain
experienced is described as throbbing (Hering, 1997: 41-45). Another feature of
Arsenicum album influenza is burning pains in the eyes with acrid lachrymation. The
eyes water considerably. The lachrymation feels hot and excoriates, further
contributing to and exacerbating the burning pains in the eyes (Boericke, 1997: 79-
83). A patient with influenza will exhibit some degree of inflammation of the
conjunctivae and watering of the eyes (Richards, 1998: 122-125).
Influenza symptoms related to the respiratory tract are usually mild at first and
usually begin with a scratchy, sore throat. There may also be substernal burning, non-
productive cough and coryza. The cough may become severe and productive as the
illness progresses (Richards, 1998: 112-125).
The Arsenicum album influenza patient will complain of burning pains in the throat
with difficulty swallowing (Gagrat, 2001: 37-38). The throat will feel swollen and
constricted. There is a scraping~ raw sensation in the throat and burning when
swallowing (Vermeulen, 1997: 179-192). The tonsils are inflamed and swollen. There
is dryness in the throat and hoarseness accompanying the throat pain (Hering, 1997:
52-53). The burning pains in the throat are ameliorated by hot application and from
eating or drinking hot things (Nash, 1997: 87-94). The Arsenicum album patient is
thirsty for small sips frequently. This thirst is unquenchable (Sankaran, 1997: 19-20).
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The patient experiencing an Arsenicum album cough will complain of a dry cough
with difficult, scanty and frothy expectorant. The sputum may be yellow or green or
may contain blood (Vermeulen, 1997: 179-192). The mucus is tenacious (Nash, 1997:
87-94). The patient experiences burning in the chest on coughing (Boger, 1995: 19-
21). The chest feels raw or excoriated (Vermeulen, 1997: 179-192). The patient
experiencing this type ofcough will be unable to lie down fearing suffocation (Boger,
1995: 19-21). The patient must sit up as soon as the cough begins (Vermeulen, 1997:
179-192). The cough is worse for lying on the back and is worse around la.m-2a.m in
the morning (Morrison, 1993: 39-44).
The patient experiencing the Arsenicum album influenza. symptoms will have
excessive sneezing that does not bring relief. There is watery, acrid nasal discharge
which drips forward but leaves the nose obstructed. The discharge excoriates the nose
(Morrison, 1993: 39-44). There may be predominantly right-sided coryza
(Vermeulen, 1997: 179-192). The discharge may be thick and yellow. There is
burning and throbbing in the nose (Hering, 1997: 46-47).
Other characteristic clinical features of influenza include prostration and generalised
body aches and pains, particularly of the legs and back (Collier and Oxford, 1993:
131). The influenza patient requiring Arsenicum album will exhibit extreme
prostration and exhaustion which may alternate with -restlessness (Morrison, 1993:
39-44). The Arsenicum album patient is weak out of proportion to the complaint
(Jouanny, 1984: 47-52). Together with profound prostration there is an irritable
weakness that makes the patient want to move around constantly (Nash, 1997: 87-94)
The patient feels better for moving around (Jouanny, 1984: 47-52). The patient is so
weak, however, that the slightest exertion exhausts him and he must lie down. This
extreme degree ofprostration can come on very rapidly (Nash, 1997: 87-94).
The Arsenicum album patient will complain of weakness and possibly intense
burning, in the lumbar region of the back (Boericke, 1997: 79-83). There will also be
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excessive weakness and exhaustion of limbs obliging the patient to lie down
(Vermeulen, 1997: 179-192).
In general, influenza may present with nausea, anorexia and fatigue (Richards, 1998:
112-125). The influenza patient with an Arsenicum album presentation of influenza
symptoms will exhibit nausea and anorexia. With acute illness there is a loss of
appetite (Vermeulen, 1997: 179-192). These patients cannot bear the sight or smell of
food and nausea sets in after eating or drinking (Boericke, 1997: 79-83).
With the extreme weakness, prostration and fatigue there is sleeplessness with
constant restlessness and tossing about. It is said that the Arsenicum album patient
feels anxious even in his sleep. The insomnia is most marked between midnight and
la.m (Morrison, 1993: 39-44). The Arsenicum album patient must have the head
raised by pillows for fear of suffocation during sleep (Boericke, 1997: 79-83).
The degree of similarity between the presentation of symptoms in the current
influenza epidemic and the presentation of an Arsenicum album type influenza was
the reason for choosing the homoeopathic remedy, Arsenicum album 30CH. Hence,
by the application of the Law of Similars, the genus epidemicus remedy for the
influenza epidemic ofthis year's winter was determined.
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CHAPTER THREE
METHODOLOGY
3.1. Study design
This study was a placebo-controlled double blind evaluation. Enrolment in the study
for four days was planned for thirty participants pre-diagnosed by the clinician with
influenza-like syndrome during an epidemic of influenza. Participants were recruited
from the Technikon Witwatersrand Homoeopathy Clinic and from a general
practitioner's medical practice in Randburg. The study was conducted from June to
August 2001.
3.2. Genus epidemicus remedy
The genus epidemicus remedy was chosen on account of personal communication
with registered homoeopathic practitioners in the general area of Johannesburg, in
which the study was conducted. The remedy that ~was most indicated for the
symptoms of the influenza epidemic at the time of the study and which was most
often prescribed by homoeopathic practitioners 'for these presenting symptoms, was
chosen and used as this year's genus epidemicus remedy. The remedy that was
chosen as this year's genus epidemicus for the influenza epidemic was Arsenicum
album. It was administered in a 30CH potency.
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3.3. Recruitment of patients
Participants recruited for the study were selected from those who had consulted a
clinician at a general practitioner's practice in Randburg or at the Technikon
Witwatersrand Homoeopathy Clinic with influenza-like symptoms and had been
diagnosed as having influenza by the clinician. The infection had to have occurred
less than 48 hours before entry into the trial. Certain criteria had to be fulfilled in
order for the patients to be viable for the study. Entry requirements and exclusion
criteria were dealt with by completion of a questionnaire (Appendix B). Patients
excluded from the study included those who were under the age of eighteen or over
sixty years of age, patients with immune system disorders or local infections, patients
who had been immunised against influenza, and patients who had taken anti-
influenzal medicines, analgesics or antibiotics in the 48 hours prior to commencement
ofthe trial.
Participants were required to give written consent (Appendix A), after having been
informed as to the nature, meaning and extent of the clinical trial. The research
participants represented a random sample of the populationsuffering from influenza
within the general area of the clinician's practice and that of the Technikon
Witwatersrand Homoeopathy Clinic.
3.4. Research procedure
Research participants who had fulfilled entry requirements and who had given their
consent were randomly allocated to' one of the two treatment groups, namely the
experimental or control group. The participants were required to complete a Patient
Profile (Appendix B) in which their personal details were recorded. The Patient
Profile also recorded the symptoms that the participants were experiencing at the time
ofentry into the study.
40
On completion of the Patient Profile (Appendix B), the participants were then asked
to complete a second questionnaire, Questionnaire 2 (Appendix D). Questionnaire 2
pertained to the genus epidemicus remedy, namely Arsenicum album 30CH. This
questionnaire was only formulated once the genus epidemicus remedy was
determined. It served to qualify the symptoms that the participants were experiencing.
The participants were asked to describe their symptoms in more detail by choosing
one of three options given on the questionnaire for each symptom or give their own
description ifnone ofthe options were appropriate.
Instructions on how and when to take the medication were given. The medication was
administered as a single dose of five pillules three times daily. The first dose of
medication was administered in the clinician's office on commencement of the study
and the following six doses were to be taken three times daily, in the morning, at
lunch and in the evening, by the participants themselves.
The participants were asked to rate the severity of their symptoms on Questionnaire 1
(Appendix C), which pertained to influenza symptoms.
The participants were instructed to contact their doctor immediately if there was any
deterioration in symptoms. On completion ofthe study, participants were requested to
return the completed questionnaires to the clinician's office. They were also required
to have a follow up consultation with the clinician and the researcher at which time
vital signs were monitored and recorded and symptoms assessed and noted.
3.4.1. Medication
The homoeopathic remedy, Arsenicum album 30CH, was provided by Natura
Laboratories. Lactose pillules were impregnated with Arsenicum album 30CH for the
experimental group. The placebo, for the control group, consisted of unmedicated
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pillules. Unmedicated placebo lactose pillules were dispensed in the same container
as the experimental medicine. The medication and placebo were packaged in 25ml
amber glass bottles and labelled accordingly.
3.4.2. Questionnaires
Participants were instructed to rate their symptoms according to a five-point scale
provided by means of Questionnaire 1 (Appendix C). This questionnaire was to be
completed six times, at designated time intervals, over the four day period of the
study. The first questionnaire was to be completed on the first day of the study in the
evening following the first dose of medication. The following four questionnaires
were to be completed twice daily, mornings and evenings, for the following two days
of the study. The final questionnaire was to be completed on the morning of the
fourth day, the last day of the study.
3.5. Data analysis
After completion of the study, all data collected from the participants was analysed
using the Mann-Whitney statistical test. The influenza-like symptoms being
investigated were analysed individually and as a totality for decrease in severity of
symptoms over the set period of time, this being four days. The extent of the decrease
in severity of symptoms between the experimental and control groups, compared to
each other, was also statistically analysed. Effectiveness was defined as a statistically
significant greater decrease in symptom severity in the experimental group, namely
Group B, as compared with the control group, namely Group A.
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CHAPTER FOUR
RESULTS
4.1. Introduction to results
All results from the study were analysed using the Mann-Whitney statistical test. The
control and experimental groups were analysed separately. Group A was determined
to be the control group and Group B the experimental group.
4.2. Analysis according to frequency
4.2.1. Age frequency
The age groups of participants were determined according to frequency as indicated
in the graph below, Figure 4.1.
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Figure 4.1. Graph depicting frequency and age of participants
The majority of participants recruited for this study feU between the ages of nineteen
and thirty-two years. The mean age of the participants was thirty years.
4.2.2. Gender frequency
Both male and female participants were recruited for this study.
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Figure 4.2. Bar graph ofgender frequency
The majority of participants recruited for this study were females. 70% of participants
were females and 30% of participants were males.
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4.2.3. Group frequency
Thirty participants were randomly allocated into one of two groups of fifteen
participants each; Group A or Group B. Once the research was completed, it was
determined from relevant sources that Group A received the placebo and was thus the
control group and Group B received the genus epidemicus remedy, Arsenicum album
30CH, and was thus the experimentalgroup.
Table 4.1. Illustrates group frequency
Group
1
Cumulative Percent II
50.0
50.0
100.0
15
15
30
Frequency Percent Valid Percent
Valid
4.3. Data obtained from Patient Profile
All the results were obtained to determine the percentage of participants suffering
from a particular symptom. The table below contains the percentage of participant
response to questions pertaining to influenza or influenza-like syndrome. The
questionnaire (Appendix B) from which this data was derived was used as a means of
recruiting suitableparticipants for this study.
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Table4.2. Illustrates percentageofparticipant responseto selectedinfluenzasymptoms
Are you suffering from a headache?
Do you have chills and shivering?
Do you have a sore throat?
Do you have a blocked nose?
Do you have a cough?
Are you feeling very tired and weak?
Do you have a nasal discharge?
Are you suffering from general body aches and pains?
Are your eyes watering?
Is this illness interfering with your daily activities?
33.3%
20
66.7%1
80.0%
6
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4.4. Data obtained from Questionnaire 2
Data from Questionnaire 2 (Appendix D) was interpreted. It described headache,
chills and shivering, sore throat, blocked or runny nose, cough, body aches and pains,
nasal discharge and watering eyes. The individual descriptions of each symptom were
analysed. The different descriptions were necessary to determine whether Arsenicum
album was the indicated genus epidemicus remedy for the influenza-like symptoms
described by the participants.
4.4.1. Headache frequency
The frequency graph below, Figure 4.3., illustrates the different types of headache
experienced by the participants. For further statistical analysis refer to Appendix E-l .
Describe your headache?
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Figure 4.3. Frequency versus headache
Throb bing of the head
A burning sensation
within the head
o The head feels hot
o Other
Participants were required to indicate the type of headache they were experiencing.
The majority of participants described their headache as ' throbbing of the head' .
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4.4.2. Chills and shivering frequency
The frequency graph below, Figure 4.4., illustrates the different types of chills and
shivering described by the participants. Refer to Appendix E-2 for further statistical
evaluations.
Describe your chills and shivering?
12
10 Chilliness alternating
with heat
>0- 8 Extremely chilly withu
c internal burning heatCD 6:::J
D" o Chills with noe 4 shiveringlL
2 o Other
0
Figure 4.4 . Frequency versus chills and shivering
From the options available, eight participants described their chills and shivering as
' chilliness alternating with heat' . The majority of participant s selected ' other' .
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4.4.3. Sore throat frequency
The frequency graph below, Figure 4.5., illustrates the different presentations of sore
throat described by the participants. Refer to Appendix E-3 for further statistical
evaluation.
Describe your sore throat?
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It feels swollen
making it difficult
to swallow
It feels dry with a
burning sensation
o It is itching and
tickling
D Other
Figure 4.5. Frequency versus sore throat
Participants were requested to indicate the type of sore throat they were experiencing.
The majority of participants described their sore throat as ' it feels swollen making it
difficult to swallow' .
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4.4.4. Blocked or runny nose frequency
The frequency graph below, Figure 4.6., illustrates the different types of blocked or
runny nose described by the participants. For further statistical analysis refer to
Appendix E-4 .
Describe your blocked or nmny nose?
14 -r-- -~-------....__.,
12 +-- - -
>- 10 +-- - -
(,)
~ 8 +-- - -
:::J
tT 6 +--- --e
11. 4
2
o
Figure 4.6. Frequency versus blocked or runny nose
It is runny and very
itchy
It is blockedwith a
lot ofsneezingthat
doesn't relieve
oThere is burning
and dryness in the
nose
o Other
Participants were required to indicate the type of blocked or runny nose they were
experiencing. The majority of participants described their blocked or runny nose as
'blocked with a lot of sneezing that doesn 't relieve' .
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4.4.5. Cough frequency
The frequency graph below, Figure 4.7., illustrates the different types of cough
experienced by the participants. Refer to appendix £ -5 for further statistical
elaboration.
Describe your cough?
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Figure 4.7 . Frequency versus cough
It is a dry cough that at
tirres becomes
productive
It is a hard, tight,
tickling, painful, hacking
cough
D It is a dry cough with a
raw feeling in the che st
DOther
From the options available, eleven of the thirty participants described their cough as a
'dry cough that at times becomes productive' and nine of the thirty participants
described their cough as a 'hard, tight, tickling, painful, hacking cough' .
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4.4.6. Nasal discharge frequency
The frequency graph below, Figure 4.8., depicts the different descriptions of nasal
discharge given by the participants. Refer to Appendix E-6 for further statistical
evaluation.
Describe yournasaldischarge?
Figure 4.8. Frequency versus nasal discharge
Participants were requested to indicate the type of nasal discharge they were
experiencing. The majority of participants described their nasal discharge as 'watery
and bums the nose' . Eight participants selected 'other'.
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4.4.7. General body aches and pains frequency
The frequency graph below, Figure 4.9., illustrates the different descriptions of
general body aches and pains given by the participants. Refer to Appendix E-7 for
further statistical evaluation.
Describe yourgeneral bodyaches and pains?
12 There is weakness in
the lowerback
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There is stiffnessin
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Figure 4.9. Frequency versus general body aches and pains
Participants were required to indicate the type of general body aches and pains they
were experiencing. From the options available, ten participants described their
general body aches and pains as 'weakness in the lower back ' and ten participants
described their body aches and pains as ' stiffuess in the limbs, neck and back ' .
53
4.4.8. Watering eyes frequency
The frequency graph below, Figure 4.10., illustrates the descriptions of watering eyes
given by the participants. For further statistical analysis refer to Appendix E-8.
Describe your Wltering eyes?
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Figure 4.10. Frequency versus watering eyes
The eyes feel swollen
and hot
The eyes are watering
and bum
DOther
Participants were required to indicate the type of watering eyes they were
experiencing. The majority of participants opted for 'other ' .
4.5. NPar tests
Results were analysed usmg the NPar statistical test. Graphs indicative of these
statistics are illustrated from Figure 4.11. to Figure 4.30. For further statistical
elaboration refer to Appendix F.
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4.6. Intensity results
4.6.1. Intensity of symptoms
During the study, participants of both Group A and Group B were requested to
complete Questionnaire 1 (Appendix C). This Questionnaire 1 was to be completed
six times over the four day period of the study at designated times. Intensity of
symptoms was determined. On a scale from 0 to 5, zero was considered most intense
and five was considered least intense.
4.6.2. General Linear Model
The results obtained from the study were analysed using the General Linear Model
statistical test. The General Linear Model illustrates estimated marginal means which
is the average intensity of each symptom for each group, Group A and Group B, over
a set period of time, this being four days. A P-value of less than P= 0.05 was
considered significant and indicated that Group B intensity was reduced more
significantly over the four days than Group A symptom intensity. Group A was
determined to be the control group and Group B was determined to be the
experimentalgroup.
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4.6.3. Headache intensity
The graph below, Figure 4.11 ., illustrates the intensity of the headache . Group B
intensity of symptoms was reduced more significantly than Group A over the
specified time interval. For further statistical evaluation refer to Appendix G-I.
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Figure 4.11. Bar graph of headache intensity over time interval 1-6
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Figure 4.12. General linear model graph of headache intensity over time interval 1-6
The average P-value for the entire specified time was P= -0,36. This indicated a
significant reduction in symptom intensity over the specified time interval.
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4.6.4. Chills and shivering intensity
The graph below, Figure 4.13., illustrates the intensity of the chills and shivering.
Group B intensity of symptoms over the specified time interval was reduced more
significantly than Group A. For further statistical evaluation refer to Appendix G-2.
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Figure 4.13. Bar graph of chills and shivering intensity over time interval 1-6
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Figure 4.14 . General linear model graph of chills and shivering intensity over time
interval 1-6
The average P-value for the entire specified time was P= -0,22. This indicated a
significant reduction in the intensity of symptoms over the specified time interval.
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4.6.5. Sore throat intensity
The graph below, Figure 4.15., indicates the intensity of the sore throat over time.
Group B intensity of symptoms was significantly reduced compared with Group A.
For further statistical evaluation refer to Appendix G-3.
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Figure 4.15. Bar graph of sore throat intensity over time interval 1-6
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Figure 4.16. General linear model graph of sore throat intensity over time interval 1-6
The average P-value for the entire specified time was P= -0,30. This indicated a
significant reduction in the intensity of symptoms over the specified time interval.
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4.6.6. Blocked nose intensity
The graph below, Figure 4.17., indicates the intensity of the blocked nose over time.
There was a significant reduction in the intensity of symptoms in Group B as
compared with Group A. For further statistical elaboration refer to Appendix G-4.
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Figure 4. 17. Bar graph of blocked nose intensity over time interval 1-6
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Figure 4.18. General linear model graph of blocked nose intensityover time interval 1-6
The average P-value for the entire specified time was P= -0,19 . This indicated a
significant reduction in the intensity of symptoms over the specified time interval.
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4.6.7. Cough intensity
The graph below, Figure 4.19., indicates the intensity of cough over time. There was
a slight significant reduction in the intensity of symptoms in Group B as compared
with Group A. For further statistical elaboration refer to Appendix G-5 .
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Figure 4.19. Bar graph of cough intensity over time interval 1-6
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Figure 4.20. General linear model graph of cough intensity over time interval 1-6
The average P-value for the entire specified time was P= -0,06. This indicated a
significant reduction in the intensity of symptoms over the specified time inte rval.
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4.6.8. Tiredness or weakness intensity
The graph below, Figure 4.21., depicts the intensity of tiredness or weakness . Group
B intensity of symptoms over the specified time interval was significantly reduced as
compared with Group A. For further statistical analysis refer to Appendix G-6.
Tiredness or weakness
4 .50
4 .00
·
3 .5 0E
0 3 .0 0Q.
E 2 .50~
'0 2 .0 0
?; 1.50
·
e
·E
Time of fi lli ng questionnaire
Figure 4.21. Bar graph of tiredness or weakness intensity over time interval 1-6
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Figure 4.22. General linear model graph of tiredness and weakness intensity over
time interval 1-6
The average P-value for the entire specified time was P= -D,44. This indicated a
significant reduction in the intensity of symptoms over the specified time interval.
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r4.6.9. Nasal discharge intensity
The graph below, Figure 4.23. , indicates the intensity of nasal discharge over time.
Group B intensity of symptoms was reduced more significantly than Group A. For
further statistical elaboration refer to Appendix G-7.
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Figure 4.23. Bar graph of nasal discharge intensity over time interval 1-6
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Figure 4.24. General linear model graph of nasal discharge intensity over time interval 1-6
The average P-value for the entire specified time was P= -0,29 . This indicated a
significant reduction in the intensity of symptoms over the specified time interval.
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4.6.10. General body aches and pains intensity
The graph below, Figure 4.25. , indicates the intensity of general body aches and pains
over time. Group B intensity of symptoms was reduced more significantly than
Group A. For further statistical elaboration refer to Appendix G-8 .
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Figure 4.25. Bar graph of general body aches and pains intensity over time interval 1-6
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Figure 4.26. General linear model graph ofgeneral body aches and pains intensity
over time interval 1-6
The average P-value for the entire specified time was P= -0,21. This indicated a
significant reduction in the intensity of symptoms over the specified time interval .
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4.6.11. Watering eyes intensity
The graph below, Figure 4.27., indicates the intensity of watering eyes over time.
Group B intensity of symptoms was reduced more significantly than Group A. For
further statistical evaluation refer to Appendix G-9 .
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Figure 4.27. Bar graph of watering eyes intensity over time interval 1-6
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Figure 4.28. General linear model graph of watering eyes intensity over time interval 1-6
The average P-value for the entire specified time was P= -0,07. This indicated a
significant reduction in the intensity of symptoms over the specified time interval.
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4.6.12. Interference of illness on daily activities intensity
The graph below, Figure 4.29., indicates the intensity of interference of illness on
daily activities over time. Group B intensity of symptoms was reduced more
significantly than Group A. For further statistical elaboration refer to Appendix G-IO.
Interference of Illness on dally activities
4.50
4 .00
·
3.50E
0 3.00Ci.
E 2 .50l;'
'0 2 .00
~ 1.5 0
·
r:
• 1.00:E
0 .50
0 .00
4
Time of filling questionnaire 6
E1 Gr oup A
_ Group B
Figure 4.29. Bar graph of interference of illness on daily activities intensity over time
interval 1-6
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Figure 4.30. General linear model graph of interference of illness on daily activities
intensityover time interval 1-6
The average P-value for the entire specified time was P= -D,40 . This indicated a
significant reduction in the intensity of symptoms over the specified time interval.
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CHAPTER FIVE
DISCUSSION
5.1. Frequency results
5.1.1. Age frequency
As depicted in Figure 4.1., the age groups of participants was determined according,
to frequency. The majority of participants were between 19 and 32 years old.
5.1.2. Gender frequency
Figure 4.2. indicated that the majority of participants recruited for the study were
females. Twenty-one participants were female and nine participants wer~male.
5.1.3. Group frequency
Thirty participants were randomly and equally divided into two groups of fifteen
participants respectively. Group A was determined to be the control group and Group
B was determined to be the experimental group.
\-
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5.2. Data obtained from Patient Profile
The participants' responses with regard to the Patient Profile (Appendix B), as
indicated in Figure 4.2., is given as a percentage ofparticipants exhibiting a particular
symptom:
• 93,3% of participants indicated that they were feeling 'very tired and
weak'
• 90% ofparticipants indicated that they were suffering from a cough
• 86,7% ofparticipants exhibited a nasal discharge
• 83,3% ofparticipants indicated they had a headache
• 33,3% ofparticipants indicated they had watering eyes
• 80% of the participants considered their symptoms to be 'interfering with
their daily activities'.
This confirmed that participants experienced symptoms characteristic of influenza or
influenza-like syndrome. These patients thus fulfilled entry requirements for the study
and were recruited as participants for the study.
.. 5.3. Data obtained from Questionnaire 2
5.3~1. Headache frequency
Figure 4.3. and Appendix E-1 indicated that 42% of all participants described their
headache as 'throbbing'. Twenty-four percent described their headache as 'the head
feels hot'. The description of 'the head feels hot' indicated Arsenicum album as the
required homoeopathic remedy. The option 'other' was chosen by 28% of
participants. Participant descriptions given under 'other' included 'aching',
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'pressure', and 'moving inside the head'. These descriptions were not indicative of
Arsenicum album as the required remedy. Five participants did not exhibit the
symptom of headache, as indicated in Table 4.2., and these five participant
descriptions were considered as 'not applicable'.
5.3.2. Chills and shivering frequency
As indicated in Figure 4.4. and Appendix E-2, 32% of participants described their
chills and shivering as 'chilliness alternating with heat'. This description is
characteristic of an Arsenicum album presentation of chilliness. Forty-four percent
indicated 'other' as their description. Twelve participants did not suffer from chills
and shivering, as seen in Figure 4.4, and these twelve participant descriptions were
therefore considered as 'not applicable'. Elaboration of the description of 'other'
included 'cold', 'chills on the back', 'extremely cold right to the bone' and 'chilly
only'. These descriptions did not conform with the Arsenicum album presentation of
chilliness.
5.3.3. Sore throat frequency
Figure 4.5. and Appendix E-3 indicated that 45% of participants described their sore
throat as 'it feels swollen making it difficult to swallow'. As indicated in Figure 4.5.,
nine participants did not exhibit a sore throat and .chose 'other' . These nine
participant descriptions where therefore considered as 'not applicable'. One of the
participants who chose 'other', further described the sore throat as 'discomfort in the
throat'. This description is not indicative of an Arsenicum album presentation of sore
throat. Fourteen percent described their sore throat as 'it feels dry with -a burning
sensation'. The descriptions of 'it feels swollen making it difficult to swallow' and 'it
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feels dry with a burning sensation' were indicative of Arsenicum album as the
required homoeopathic remedy for the symptom of 'sore throat'.
5.3.4. Blocked or runny nose frequency
As indicated in Figure 4.6. and Appendix E-4, the majority of participants chose the
description of 'it is blocked with a lot of sneezing that doesn't relieve' to describe
their blocked or runny nose. This shows that 46% of all participants had an
Arsenicum album presentation of the symptoms. The description 'other' was chosen
by 36% of participants. On further elaboration, three participants described their
blocked or runny nose as 'runny only'. Other descriptions included 'runny, blocked
and burning', 'runny and itchy with sneezing', 'blocked alternating with runny' and
'blocked and dripping'. These descriptions may still be indicative of Arsenicum
album as the required remedy, however, these descriptions are not characteristic of
the remedy.
5.3.5. Cough frequency
Figure 4.7. and Appendix E-5 indicated that 37% of all participants described their
cough as 'a dry cough that at times becomes productive'. Thirty percent described
their cough as 'a dry cough with a raw feeling in the chest'. Both these symptom
descriptions were indicative of an Arsenicum album presentation of cough. Of the six
participants that chose 'other', three did not have the symptom and their description
was thus considered 'not applicable'. Descriptions given by the remaining three
participants were 'deep cough with phlegm', 'dry, hoarse cough', and 'wet cough'.
These descriptions were not indicative ofArsenicum album as the required remedy.
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5.3.6. Nasal discharge frequency
Figure 4.8. and Appendix E-6 showed that 31% of participants described their nasal
discharge as 'watery and burns the nose'. This is a very characteristic symptom of an
Arsenicum album presentation of influenza. Twenty-four percent of participants
described their nasal discharge as 'the mucus is yellow in colour'. Again, this is
indicative ofArsenicum album type influenza. Eight participants described their nasal
discharge as 'other'. Four participants who selected 'other' did not exhibit a nasal
discharge and their descriptions were thus considered 'not applicable'. The remaining
four participants who chose 'other' elaborated on the description, describing their
nasal discharge as 'watery'. This description does not indicate Arsenicum album as
the required remedy.
5.3.7. General body aches and pains frequency
As seen in Figure 4.9. and Appendix E-7, 34% of participants chose 'there is
weakness in the lower back' to describe their ~ches and pains. Thirty-four percent of
participants gave the description of 'there is stiffness in the limbs, neck and back' for
their aches and pains. The first description is indicative of Arsenicum album as the
required remedy. A person experiencing Arsenicum al5um-type body aches and pains
would feel 'great weakness from the slightest effort'. Only 7% of all participants
chose this as their description. Of the eight participants that selected 'other', six
participants did not exhibit the symptom and their descriptions were considered as
'not applicable'. The remaining two participants described their general body aches
and pains as 'a general weak feeling' and 'aching in joints'. These two descriptions
are not indicative ofArsenicum album as the required remedy.
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5.3.8. Watering eyes frequency
As depicted in Figure 4.10. and Appendix E-8, 79% ofparticipants selected 'other' as
their description for.watering eyes. Twenty participants did not exhibit the symptom
and would have selected 'other' as none of the descriptions applied. Three
participants that did exhibit the symptom of 'watering eyes' and described their
watering eyes as 'other', elaborated on that description by saying that their eyes were
'slightly watery'. Twenty-one percent of participants described their watering eyes as
'the eyes are watering and burn'. This is a marked feature of an Arsenicum album
presentation of influenza. The third option of 'there is blurred vision with heavy,
droopy eyes' (refer to Appendix D) was not reflected in Figure 4.10. or Appendix E-8
as none ofthe participants chose the description.
5.4. Intensity results
5.4.1. Headache intensity
In Figure 4.11. and Figure 4.12. it can be seen that Group B intensity of symptoms
was significantly reduced when compared with Group A. The P-value was P= -0,36
(Appendix G-l). This indicated that there was indeed a statistically significant
difference as P= -0,36 is less than P= 0,05. It can therefore be deduced that
Arsenicum album 30CH is effective in reducing the intensity of 'headache' over the
specified period oftime.
5.4.2. Chills and shivering intensity
Figure 4.13. and Figure 4.14. indicated a significant reduction in intensity of
symptoms between the control group, Group A, and the experimental group, Group
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B. The average P-value (Appendix G-2) was 'calculated to be P= -0,22 and
statistically verifies the significant difference in intensity of symptoms over the
specified time interval. Arsenicum album 30CH has thus been shown to be effective
in significantly reducing the intensityof 'chills and shivering' over the specified time
interval.
5.4.3. Sore throat intensity
Figure 4.15. and Figure 4.16. show intensity of 'sore throat' over the specified time
interval. From these graphs it is evident that Group B intensity of symptoms was
significantly reduced as compared with Group A. The average P-value was calculated
to be P= -0,30 (Appendix G-3) which showed a statistically significant difference in
intensity of symptoms between the two groups over the specified time interval. This
also shows that Arsenicum album 30CH is effective in reducing the severity of 'sore
throat' over the specified time interval.
5.4.4. Blocked nose intensity
The significant difference in intensity of symptoms between Group A and Group B
with regard to 'blocked nose' is indicated in Figure 4.17. and Figure 4.18. The
average P-value (Appendix G-4) for this symptom intensity over the specified time
interval was calculated to be P= -0,19. As there is a significant difference, it is
determined that Arsenicum album 30CH is effective in reducing the intensity of
'blocked nose' over the specified time interval.
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5.4.5. Cough intensity
The average P-value calculated for 'cough' intensity over the specified time interval
was P= -0,06 (Appendix G-5). This P-value indicates a slight significant reduction in
intensity of symptoms over time interval between Group A and Group B. This
significant reduction of intensity of symptoms over the specified time interval for
'cough' is depicted in Figure 4.19. and Figure 4.20. It can thus be deduced that
Arsenicum album 30CH was effective in reducing the intensity of the 'cough' over
the specified time interval.
5.4.6. Tiredness or weakness intensity
Figure 4.21. and Figure 4.22. indicated that 'tiredness and weakness' intensity
between Group A and Group B over the specified time interval was significantly
reduced. The average P-value for this symptom was calculated to be P= -0,44
(Appendix G-6). This value statistically verifies the reduction in intensity of symptom
over the specified time interval and, thus, shows Arsenicum album 'lOCH to have
been successful in the treatment of 'tiredness or weakness'.
5.4.7. Nasal discharge intensity
There is a significant reduction in 'nasal discharge' intensity over the specified time
interval between Group A and Group B as indicated in Figure 4.23. and Figure 4.24.
The average P-value calculated for this symptom (Appendix G-7) was P= -0,29. This
value statistically verifies this reduction in intensity and indicates the effectiveness of
Arsenicum album 30CH in reducing symptom intensity over the specified time
interval for the symptom of 'nasal discharge'.
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5.4.8. General body aches and pains intensity
Figure 4.25. and Figure 4.26. indicated a significant reduction in intensity of
symptoms between Group A and Group B. The average P-value calculated for this
symptom, P= -0,21, confirms this significant reduction in intensity over time interval.
From this P-value (Appendix G-8) it can be deduced that Arsenicum album 30CH is
effective in reducing the intensity of 'general body aches and pains' over the
specified time interval.
5.4.9. Watering eyes intensity
Figure 4.27. and Figure 4.28. indicated a slight significant reduction in intensity of
'watering eyes' over the specified time interval between Group A and Group B. The
average P-value (Appendix G-9) for this symptom was calculated to be P= -0,07.
This significant reduction in intensity of symptom over the specified time interval
indicates that Arsenicum album 30CH is effective in reducing the intensity of
'watering eyes'.
5.4.10. Interference of illness on daily activities intensity
Figure 4.29. and Figure 4.30. indicated that the intensity of 'interference of illness on
daily activities' in Group B was more significantly reduced than in Group A. The
average P-value (Appendix G-IO) calculated for this symptom was P= -0,40. This P-
value indicates the effectiveness of Arsenicum album 30CH in reducing symptom
intensity over the specified time interval for 'interference of illness on daily
activities' .
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CHAPTER SIX
CONCLUSIONS AND RECOMMENDATIONS
6.1. Conclusion
6.1.1. Frequency results
All participants recruited for this study exhibited characteristic symptoms of
influenza or influenza-like syndrome. This was determined from the Patient Profile
(Appendix B). All results from the Patient Profile where obtained and the percentage
of participants exhibiting a particular symptom was determined, as indicated in Table
4.2.
Thirty participants were equally and randomly divided into two groups of fifteen
participants each. On conclusion of the study, Group A was determined to be the
control group and Group B was determined to be the experimental group.
6.1.2. Data obtained from Questionnaire 2
It was denoted from Figure 4.3. to Figure 4.10. and Appendix E-l to Appendix E-8
that the participant's descriptions of symptoms indicated that Arsenicum album 30CH
was the required homoeopathic remedy for the treatment of the influenza-like
syndrome. This further indicated that the selection ofArsenicum album 30CH as the
genus epidemicus remedy for the influenza epidemic of the winter of 2001 was
appropriate.
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6.1.3. Intensity results
Figure 4.11. to Figure 4.30. reflect symptom intensity over the specified time interval.
It is evident from the P-value calculations (Appendix G) for each of the symptoms
that there was a significant decrease in the severity of symptoms in the experimental
group, Group B, over the specified time interval. The most profound decrease in the
severity of symptoms over the specified time interval included 'headache intensity',
'tiredness or weakness intensity', and 'interference of illness on daily activities
intensity'. These symptoms showed the most marked improvement. The least
significant decrease in the severity of symptoms over the specified time interval
included 'watering eyes intensity' and 'cough intensity'.
From this evidence it can be determined that the genus epidemicus remedy chosen for
this year's influenza epidemic, namely Arsenicum album lOCH, was effective in
reducing the severityof symptoms. This research serves as an indication of the ability
of the homoeopathic remedy Arsenicum album lOCH to be effective in the treatment
of influenza and influenza-like syndrome. In addition, this research further
compounds evidence that the efficacy of homoeopathic remedies is not as a result of
the placebo effect. This research has ultimately contributed to the data-base of
information available to indicate the therapeutic efficacy ofhomoeopathic remedies.
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6.2. Recommendations
Numerous recommendations can be suggested for research in a similar field:
• Further research needs to be conducted to determine whether the results obtained
with Arsenicum album 30CH in the treatment of influenza are conclusive. This
would verify the results obtained in this study.
• Research should also be conducted on a larger sample group. This will reflect a
more accurate statistical evaluation of the efficacy of the homoeopathic remedy
Arsenicum album 30CH in the treatment of influenza.
• It may be advisable to conduct further experimentation on the treatment of
influenza with varying potencies of Arsenicum album. It is known that
homoeopathic remedies have varying actions at different potencies. It may be
worthwhile to determine the efficacy of Arsenicum album in higher and lower
potencies in the treatment of influenza.
• It may also be beneficial to administer the homoeopathic remedy more frequently
and over a longer duration to assess improvement after a longer period of time
and to determine whether increasing the dosage has any effect on efficacy of the
remedy in the treatment ofinfluenza.
• To further streamline the research, testing participants for the influenza virus
using an iri-office assay and recruiting only those testing positive for the influenza
virus, could eliminate variables' in the study and make the sample group more
homogenous.
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• Studies could be conducted that compare the efficacy of Arsenicum album as a
treatment for influenza with the conventional means of treatment, that is,
treatment with antiviral medication. Further research could determine whether
intervention with homoeopathic treatment is more effective in facilitating
improvement in symptoms than the administration ofallopathic treatment.
• Research conducted could also determine the possible benefits of combining both
allopathic and homoeopathic treatment for influenza.
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APPENDIX A
SUBJECT INFORMATION AND CONSENT FORM
The Efficacy ofthe Genus Epidemicus Remedy in the Treatment ofInfluenza
The purpose of this study is to determine the efficacy of the genus epidemicus
remedy in the treatment of influenza. The participant has been diagnosed as having
influenza and has agreed to partake in this study to aid in the search for new methods
of treating influenza.
All subjects participating in this study must be between 18 and 60 years of age, must
not be immunised against influenza or have taken any form of anti-influenzal
medication 48 hours prior to commencement of this study. If the participant chooses
to partake in this study, then he or she will be randomly placed into one oftwo groups
of fifteen participants. These groups represent the experimental (treatment) group and
the control group. Neither the researcher nor the subjects will know who will receive
the treatment and who will receive the placebo.
All subjects will be asked to complete an initial Patient Profile (Appendix B), under
the supervision of the researcher and clinician. Participants will be requested to
complete a second questionnaire, Questionnaire 2 (Appendix D). Participants will
also be asked to complete Questionnaire 1 (Appendix C) six times, at designated
intervals, over the four day period of the study. The first questionnaire is to be
completed in the evening of the first day of the study, following the first dose of
medication. The following four questionnaires are to be completed twice daily,
morning and evening, for the following two days ofthe study. The final questionnaire
is to be completed in the morning ofthe fourth day, the last day ofthe study.
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It is requested that the participant read through each question carefully before
answering and that all questions be answered honestly. No questions are to be
omitted. At the end of the four days, all completed questionnaires are to be returned
to the researcher. A follow up consultation will be conducted by the clinician with the
researcher, and vital signs monitored and recorded.
The participant will be requested to take the medication; the first dose will be
administered in the consulting rooms of the clinician, under the supervision of the
researcher, on commencement of the study. The following six doses are to be taken
three times daily; in the morning, at lunch and in the evening, for the following two
days. It is important that the participant takes the medication fifteen minutes after
eating or drinking as the medication is best absorbed in a clean mouth. The
medication will be provided free ofcharge.
To the best of the researcher's knowledge there are no anticipated risks involved in
this study. The potential benefit for those who receive the study medicine is a rapid
improvement of symptoms of influenza. All participants in this study, irrespective of
which group (experimental or control), will contribute to medical and homoeopathic
knowledge, possibly resulting in an improvement in the future management and
treatment of influenza..
Any complications arising during the period ofthe study will immediately be referred
to the clinician, and participants will be withdrawn from the study. Contact details of
the clinician will be made available to the participant.
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Participation in this study is voluntary and the subject is free to refuse to participate
or to withdraw his or her consent and to discontinue his or her participation at any
time. A signed copy of this consent form will be made available to the participant.
The researcher has fully explained the procedures, including those which are
investigational, and has explained their purpose. The researcher has asked whether or
not any questions have arisen regarding the procedures and has answered these
questions to the best ofher ability.
DATE: RESEARCHER:
Contact number: 082 346 3097
I have been fully informed as to the procedures to be followed, including those which
are investigational, and have been given a description of the attendant discomforts,
risks and benefits to be expected and the appropriate alternate procedures. In signing
this consent form I agree to this method of treatment and I understand that I am free
to withdraw my consent at any time. I understand also' that if I have any questions, at
any time, they will be answered.
DATE: PARTICIPANT:
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APPENDIXB
PATIENT PROFILE
Name:
Address:
Telephone no.:
Age:
Gender:
Remedy reference no.:
Date:
YES NO
1. Are you suffering from a headache? D D
2. Do you have chills and shivering? D D
3. Do you have a sore throat? D D
4. Do you have a blocked nose? D D
5. Do you have a cough? D D
6. Are you feeling very tired and weak? D D
7. Do you have a nasal discharge? D D
8. Are you suffering from general body aches and pains? D D
9. Are your eyes watering? D D
10. Is this illness interfering with your daily activities? D D
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APPENDIXC
PATIENT QUESTIONNAIRE 1
Name:
Date:
Time offilling in questionnaire: Morning Evening (please tickappropriate one)
The rating scale below is designed to measure the degree to which you are suffering from the
following symptoms. Please make a cross in the box that describes most accurately the
frequency and intensity of your symptoms. Please answer these questions as honestly as you
can.
I - the symptom is much worse
2 - the symptom is slightly worse
3 - there is no change
4 - the symptom is slightly better
5 - the symptom is much better
1 2 3 4 5
1. How would you rate your headache?
2. How would you rate your chills and shivering?
3. How would you rate your sore throat?
4. How would you rate your blocked nose?
.5.' How would you rate your cough?
6. How would you rate your tiredness and weakness?
7. How would you rate your nasal discharge?
8. How would you rate your general body aches and pains?
9. How would you rate your watering eyes?
10. How would you rate the interference of the illness on your
daily activities?
DDDDD
DDDDD
DDDDD
DDDDD
DDDDD
DDDDD
DDDDD
DDDDD
DDDDD
DDDDD
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APPENDIXD
PATIENT QUESTIONNAIRE 2
IName:
Please make a cross in the box that describes most accurately the type of symptoms
you are experiencing. Please answer these questions as honestly as you can.
1. Describe your headache?
a) Throbbing ofthe head
b) A burning sensation within the head
c) The head feels hot
d) Other. Please specify:
2. Describe your chills and shivering?
a) Chilliness alternating with heat
b) Extremely chilly with internal burning heat
c) Chills with no shivering
d) Other. Please specify:
3. Describe your sore throat?
a) It feels swollen making it difficult to swallow
b) It feels dry with a burning sensation
c) It is itching and tickling
- d) Other. Please specify:
D
D
D
D
D
D
D
D
D
D
D
D
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4. Describe your blocked or runny nose?
a) It is runny and very itchy
b) It is blocked with a lot ofsneezing that doesn't relieve
c) There is burning and dryness in the nose
d) Other. Please specify:
5. Describe your cough?
a) It is a dry cough that at times becomes productive
b) It is a hard, tight, tickling, painful, hacking cough
c) It is a dry cough with a raw feeling in the chest
d) Other. Please specify:
6. Describe your nasal discharge?
a) The mucus is greenish in colour
b) The mucus is yellow in colour
c) The discharge is watery and it burns the nose
d) Other. Please specify:
7. Describe your general body aches and pains?
a) There is weakness in the lower back
b) There is stiffness in the limbs, neck and back
c) There is great weakness from the slightest effort
d) Other. Please specify:
8. Describe your watering eyes?
a) The eyes feel swollen and hot
b) The eyes are watering and burn
c) There is blurred vision with heavy, droopy eyes
d) Other. Please specify:
D
a
D
D
D
D
D
D
D
D
D
8
D
D
D
D
B
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APPENDIXE
Frequency tables
APPENDIX E-l: Headache frequency
Cumulative Perce
APPENDIX E-2: Chills and shivering frequency
Describe our chills and shiverin ?
13.34
8
I Frequency I Pereeqt
Extremely chilly with
internal burnin heat
Chilliness alternating with
heat
Valid
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APPENDIX E-3: Sore throat frequency
Percent Valid Percent
APPENDIX E-4: Blocked or runny nose frequency
Describe
Frequency
64.3
to 33. 100.0
28 93.
2 6.7
30 100.
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APPENDIX E-5: Cough frequency
Valid
APPENDIX E-6: Nasal discharge frequency
umulative Perc
Valid
The mucus is yellow in
colour
The discharge is watery and
it burns the nose
Other
Tota~I~======lF===-:
tern
alid Perce:ntll Cumulative ]
17.2
24.1
31.0
27.6
100.0
93
APPENDIX E-7: General body aches and pains frequency
umulative Percent
34.5
APPENDIX E-8: Watering eyes frequency
Valid
6.7
Valid Percent Cumulative Perce
8.3
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APPENDIXF
Mann-Whitney test and Npar test
APPENDIX F-l: Headache
NParTest
203.00
244.50
220.50
262.00
13.53
17.47
12.93
18.07
Mann-Whitney Test
Ranks
QI T6 I
QI T5 I
Test Statistics(b)
.355\
.412(a) I
212.50
-.925
I .935(a) II
I II QI_TI_II
1"':':M~a==nn"'":-w~bi==tn==eY-=U~====~II==--1I;;;;:;0.-=50==011~==-=~J~==-
Wilcoxon W 'I 230.500 i1F§='~~========l1====""'_=.09=:'9\1?==""'~'=(F=::::::="""
I .92111
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APPENDIX F-2: Chills and shivering
NParTests
220.501
185.50 I
Mann-Whitney Test
Ranks
Test Statistics b
Q2 T2 1
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APPENDIX F-3: Sore throat
NParTests
Mann-Whitney Test
Maximum I
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APPENDIX F-4: Blocked nose
NParTests
219.00
246.00
204.001
Sum ofRanks
17.40
13.60 I
Mann-Whitney Test
Ranks
Q4 T5 1
Test Statistics b
-1.259
84.000
204.000
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APPENDIX F-5: Cough
NParTests
224.00
241.00
Sumof Ranks
====~227.00
14.70
16.30
MeanRank
Mann-Whitney Test
Ranks
-.515
220.500
100.500
Q5 T6 1 I
- - \
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APPENDIX F-6: Tiredness or weakness
NParTests
Q6 T3 1
B
Total
ot correctedfor ties.
b Grouping Variable:Group
Q6 T6 1 I
- - ,
;
210.500 I
-.9601
100
APPENDIX F-7: Nasal discharge
NParTests
Mann-Whifne U
WiIcoxonW
rrectedfor ties.
b GroupingVariable: Grou
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APPENDIX F-8: General body aches and pains
NParTests
Mann-Whitney Test
Ranks
Q8_T'4_11108 T5 1
Test Statistics b
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APPENDIX F-9: Watering eyes
NParTests
213.00
199.50
193.00
206.50
Sum of Ranks
14.20
14.85
Mean Rank
Mann-Whitney Test
Ranks
.801J
-.252
.8~~J
213.000 !
IQ9 T6 l~l
93.00086.5001
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APPENDIX F-IO: Interference of illness on daily activities
NParTests
184.50
250.50
Sum of Ranks
Mann-Whitney Test
Ranks
.023(a)
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APPENDIXG
Intensity tables
APPENDIX G-l: Headache intensity
Symptoml QEl 1 QMll QE2 1 QM2 1 QE3 1 QM3 1
Group A 3.00 3.40 3.60 3.33 3.47 3.67
GroupB 3.33 3.87 3.33 4.00 4.07 4.07
Pvalue -0.33 -0.47 0.27 -0.67 -0.60 -0.40
Average P-value for headache intensity: P= -0.36
APPENDIX G-2: Chills and shivering intensity
Symptom2 QEl_2 QMl2 QE22 QM22 QE32 QM32
Group A 3.33 3.47 3.73 3.33 3.67 3.87
GroupB 3.21 4.00 3.92 3.85 4.21 4.21
p-value 0.12 -0.53 -0.19 -0.52 -0.54 0.34
Average P-value for chills and shivering intensity: P= -0.22
APPENDIX G-3: Sore throat intensity
Symptom3 QEl3 QMl3 QE23 QM23 QE33 QM33
Group A 3.07 3.33 3.47 3.27 3.47 3.53
Group B 3.00 3.53 3.60 3.67 4.07 4.33
p-value 0.07 -0.20 0.13 -0.40 -0.60 -0.80
Average P-value for sore throat intensity: P= -0.30
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APPENDIX G-4: Blocked nose intensity
Symptom4 QE14 QM14 QE24 QM2 4 QE34 QM34
Group A 3.07 2.93 3.33 2.87 3.27 3.67
GroupB 3.00 3.27 3.27 3.40 3.60 3.73
p-value 0.07 -0.34 0.06 -0.53 -0.33 -0.06
Average P-value for blocked nose intensity: p~ -0.19
APPENDIX G-5: Cough intensity
Symptom5 QE15 QM15 QE25 QM25 QE35 QM35
Group A 3.00 2.93 3.53 2.80 3.27 3.33
GroupB 3.00 2.93 3.27 3.07 3.47 3.47
p-value 0.00 0.00 0.26 -0.27 -0.20 -0.14
Average P-value for cough intensity: P= -0.06
APPENDIX G-6: Tiredness or weakness intensity
Symptom6 QE16 QM16 QE2_6 QM26 .QE36 QM36
Group A 3.07 3.33 3.33 3.00 3.33 3.87
GroupB 3.20 3.73 3.73 3.71 3.93 4.27
p-value -0.13 -0.40 -0.40 -0.71 -0.60 -0.40
Average P-value for tiredness and weakness intensity: P= -0.44
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APPENDIX G-7: Nasal discharge intensity
Symptom7 QEl_7 QM17 QE2_7 QM2_7 QE3_7 QM3_7
Group A 2.80 2.87 3.33 2.67 3.27 3.20
GroupB 3.07 3.00 3.27 3.27 3.53 3.73
p-value -0.27 -0.13 0.06 -0.6 -0.26 -0.53
Average P-value for nasal discharge: P= -0.29
APPENDIX G-8: General body aches and pains intensity
Symptom8 QEl_8 QM18 QE2_8 QM2_8 QE38 QM38
Group A 3.13 3.33 3.33 3.27 3.60 3.87
GroupB 3.33 3.60 3.67 3.40 3.73 4.07
p-value -0.20 -0.27 -0.34 -0.13 -0.13 -0.20
Average P-value for general body aches and pains intensity: P= -0.21
APPENDIX G-9: Watering eyes intensity
Symptom9 QE19 QM19 QE29 QM29 . QE39 QM39
Group A 3.00 3.20 3.20 3.00 3.33 3.53
Group B 3.15 3.31 3.31 3.15 3.31 3.46
. p-value -0.15 -0.11 -0.11 -0.15 0.02 0.07
Average P-value for watering eyes intensity: P= -0.07
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APPENDIX G-IO: Interference of illness on daily activities intensity
Symptom QECI0 QM1_I0 QE2_10 QM2_10 QE3_10 QM3_10
10
Group A 3.00 3.47 3.33 2.67 3.27 3.53
GroupB 2.93 3.57 3.50 3.71 3.86 4.07
p-value 0.07 -0.10 -0.17 -1.04 -0.59 -0.54
Average P-value for interference of illness on daily activities intensity: P= -DAD
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